Lipid-conjugated polyamide compounds and related compositions and methods thereof

ABSTRACT

In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.

This application is a divisional of U.S. Ser. No. 09/132,808, filed Aug.12, 1998, now U.S. Pat. No. 6,197,332 which claims the benefit of U.S.Provisional Application No. 60/054,743, filed Aug. 13, 1997, both ofwhich are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to lipid-conjugated polyamide compounds,methods for making them, as well as compositions and methods for theiruse, such as, for example, in the delivery of biologically active agentsto cells.

BACKGROUND OF THE INVENTION

The discovery of new therapeutic agents having increasingly complexmolecular structure has presented new challenges related to how they canbe efficiently delivered to targeted sites. For example, recentdevelopments in recombinant DNA technology and human genomecharacterization have enabled identification of the moleculer origins ofmany genetic and acquired diseases and construction of appropriateplasmids containing desired genes. However, the efficient delivery ofthese large and heavily charged constructs, having molecular weights ofup to tens of millions of daltons and containing several tens ofthousands of negative charges into cells remains a substantialchallenge. Studies evaluating the use of neutral and cationic liposomestructures as vehicles for the delivery of polynucleotides to cells havemet with limited success, as these encapsulated structures are ratherlarge and unstable.

Accordingly, compounds that can be used as effective vehicles for theefficient delivery of large complex agents, such as polynucleotides, tocells would be highly desirable.

SUMMARY OF THE INVENTION

The present invention is directed to lipid-conjugated polyamidecompounds and compositions thereof that are particularly useful in thedelivery of bioactive agents to cells.

Specifically, the present invention provides lipid-conjugated polyamidecompounds having the general formula:

wherein n is an integer selected from 1 to about 48 and m is an integerselected from about 2 to about 48,

wherein R₁ for each monomeric unit,

 and R_(a) are independently selected from the group consisting of ahydrogen atom; a hydroxy group; an amino group; a carboxyl group; asulfonyl group; —SH; an optionally substituted, branched or straightchain aliphatic group having from about 1 to about 8 carbon atoms in abackbone structure that optionally contains nitrogen, oxygen, sulfur,and phosphorus, wherein said aliphatic group optionally has one or moredouble or triple bonds; an optionally substituted aryl group having fromabout 3 to about 12 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfur, and phosphorus; an optionallysubstituted arylalkyl group having from about 3 to about 12 carbon atomsin a backbone structure that optionally contains nitrogen, oxygen,sulfur, and phosphorus, wherein the alkyl component of said arylalkyloptionally has one or more double or triple bonds; and a lipid moietythat is optionally bonded to a linker moiety,

wherein R₁ is not a hydrogen atom for at least one monomeric unit,

wherein R_(c) is selected from a hydrogen atom; a hydroxy group; anamino group; a hydrazine group; a sulfonyl group; —SH; an optionallysubstituted, branched or straight chain aliphatic group having from 1 toabout 8 carbon atoms in a backbone structure that optionally containsnitrogen, oxygen, sulfur, and phosphorus, wherein said aliphatic groupoptionally has one or more double or triple bonds; an optionallysubstituted aryl group having from about 3 to about 12 carbon atoms in abackbone structure that optionally contains nitrogen, oxygen, sulfur,and phosphorus; an optionally substituted arylalkyl group having fromabout 3 to about 12 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfur, and phosphorus, wherein the alkylgroup of said arylalkyl optionally has one or more double or triplebonds; and a lipid moiety that is optionally bonded to a linker moiety,

wherein when R₁, R_(a), or R_(a) is an aryl or arylalkyl group havingfewer than about 5 carbon atoms in a backbone structure, said backbonestructure further comprises one or more heteroatoms,

wherein W for each monomeric unit is independently selected from anoptionally substituted, branched or straight chain divalent moietyhaving from 1 to about 50 atoms and optionally, one or more double ortriple bonds in a backbone that contains carbon and optionally containsnitrogen, oxygen, sulfur, and phosphorus, wherein said optionalsubstitution of W may be a lipid moiety that is optionally bonded to alinker moiety,

wherein said lipid moiety is a hydrophobic or amphipathic moietyselected from the group consisting of:

(i) optionally substituted aryl or arylalkyl moieties having from about14 to about 50 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfur, and phosphorus, wherein the alkylcomponent of said arylalkyl optionally has one or more double or triplebonds; and

(ii) optionally substituted, branched or straight chain aliphaticmoieties having from about 10 to about 50 carbon atoms in a backbonestructure that optionally contains nitrogen, oxygen, sulfur, andphosphorus, wherein said aliphatic moieties optionally have one or moredouble or triple bonds, and

wherein at least one of R_(a), R_(c), W for a single monomeric unit andR₁ for a single monomeric unit comprises a lipid moiety optionallybonded to a linker moiety.

The present invention also provides a method of synthesizinglipid-conjugated polyamide compounds, said method comprising:

a) contacting

(1) a lipid reactant, with

(2) an oligomer reactant, wherein said oligomer reactant has the generalformula:

 wherein n is an integer selected from 1 to about 48, and m is aninteger from about 2 to about 48,

wherein each T_(a) and T_(c) is independently selected from a terminalgroup and a reactive moiety that is capable of further reaction withsaid lipid reactant,

wherein R₁ for each monomeric unit,

in said oligomer reactant is selected from the group consisting of ahydrogen atom; a hydroxy group; an amino group; a carboxyl group; asulfonyl group, —SH; an optionally substituted, branched or straightchain aliphatic group having from 1 to about 8 carbon atoms in abackbone structure that optionally contains nitrogen, oxygen, sulfur,and phosphorus, wherein the aliphatic group optionally has one or moredouble or triple bonds; an optionally substituted aryl group having fromabout 3 to about 12 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfur, and phosphorus; an optionallysubstituted arylalkyl group having from about 3 to about 12 carbon atomsin a backbone structure that optionally contains nitrogen, oxygen,sulfur, and phosphorus, wherein the alkyl group of said arylalkyloptionally has one or more double or triple bonds; and a reactive moietythat is capable of further reaction with said lipid reactant,

wherein when R₁, R_(a), or R_(c), is an aryl or arylalkyl group havingfewer than about 5 carbon atoms in a backbone structure, said backbonestructure further comprises one or more heteroatoms,

wherein R₁ is not a hydrogen atom for at least one monomeric unit,

wherein W for each monomeric unit is selected from an optionallysubstituted, branched or straight chain divalent moiety having from 1 toabout 50 atoms in a backbone that contains carbon, and optionallycontains nitrogen, oxygen, sulfur, and phosphorus, and optionally one ormore double or triple bonds, wherein said optional substitution of W maybe a reactive moiety that is capable of further reaction with said lipidreactant,

wherein at least one of T_(a), T_(c), W for a single monomeric unit, orR₁ for a single monomeric unit comprises a reactive moiety that iscapable of further reaction with said lipid reactant; then

b) reacting said lipid reactant with said oligomer reactant to conjugatethe lipid reactant to the oligomer reactant.

In another embodiment, the present invention provides a compositioncomprising a lipid-conjugated polyamide compound of the presentinvention and a biologically active agent.

In yet another embodiment, the present invention provides a method forinducing the uptake of a biologically active agent by a cell, saidmethod comprising:

providing a composition comprising an effective amount of a biologicallyactive agent and a lipid-conjugated polyamide compound of the presentinvention; then

contacting a biological sample with an effective dose of saidcomposition,

wherein said biological sample comprises a cell.

In still another embodiment, the present invention provides a method forinducing the uptake of a biologically active agent by a cell in vivo,said method comprising:

providing a composition comprising an effective amount of a biologicallyactive agent and a lipid-conjugated polyamide compound of the presentinvention; then

administering an effective dose of said composition to a subject.

In a further embodiment, the present invention provides a method ofexpressing a gene in a mammal, said method comprising:

administering a polynucleic acid complexed with a lipid-conjugatedpolyamide compound of the present invention to a mammal,

wherein said polynucleic acid is capable of functionally expressing saidgene in said mammal, and

wherein said complex is effective at transfecting said gene into a cellin said mammal.

In another embodiment, the present invention provides a method forsubstantially inhibiting nuclease-induced polynucleotide degradation,said method comprising:

contacting a polynucleotide with a degradation-inhibiting quantity of alipid-conjugated polyamide compound, and

introducing the polynucleotide and the lipid-conjugated polyamidecompound into a nuclease-containing environment.

In still a further embodiment, the present invention provides a methodof making a stable preparation of a polynucleic acid complexed with adelivery vehicle, said method comprising:

a) providing a polynucleic acid in a first liquid carrier as a dilutepolynucleic acid solution that is substantially precipitant-free;

b) providing a delivery vehicle-forming compound in a second liquidcarrier as a delivery vehicle solution that is substantiallyprecipitant-free;

c) combining said dilute polynucleic acid solution with said deliveryvehicle solution to form a dilute preparation of deliveryvehicle/polynucleic acid complex; then

d) reducing the volume of said dilute preparation to form a stablepreparation of delivery vehicle/polynucleic acid complex,

wherein the concentration of polynucleic acid in said stable preparationis higher than the concentration of polynucleic acid in said dilutepolynucleic acid solution, and

wherein said stable preparation is substantially precipitant-free.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a reaction scheme for preparing lipid-conjugated polyamidecompounds.

FIG. 2 is a plasmid map of vector CMVkm2.

FIG. 3 shows the effect of the +/− charge ratio of a complex of plasmidDNA (pCMVkmLUC) and a lipid-conjugated polyamide of the presentinvention (i.e., Compound 16 from Table 2) on the transfection of HT1080cells. Luciferase activity in transfected cells is shown on the y-axisin (pg/20 μl) and the +/− charge ratio is shown on the x-axis. The openbars refer to cells grown in FCS-supplemented medium and the shaded barsrefer to cells grown in OptiMEM (i.e., serum-free medium).

FIG. 4 shows the relationship between transfection efficiency and totalnumber of monomeric units in the oligomeric moiety of lipid-conjugatedpolyamide compounds of the present invention. Luciferase activity (allnormalized to luciferase activity corresponding to the 36-mer (i.e.,n=3, m=12 with reference to formula (I))) in transfected HT1080 cells isshown on the y-axis and length of oligomer is shown on the x-axis. Thelipid-conjugated polyamide/DNA complexes had a +/− charge ratio of 2:1.

FIG. 5 shows a comparison in transfection efficiency betweenDMPE-conjugated polyamide compounds (i.e., Compounds 16 and 23) andDOPE-conjugated polyamide compounds (i.e., Compounds 20 and 24). Theopen bars refer to cells grown in FCS-supplemented medium and the shadedbars refer to cells cultured in optiMEM (i.e., serum-free medium).

FIG. 6 shows luciferase expression in Balb/C mouse lung, liver, andspleen tissue after in vivo transfection with lipid-conjugated polyamidecompound (Compound 16)/pCMVkmLUC complex.

FIG. 7 shows zeta potential stability over a period of 8 days of aformulation of lipid-conjugated polyamide (Compound 16)/DNA complex,prepared by the “dilution-concentration” formulation method of thepresent invention.

FIG. 8 shows zeta potential stability over a period of 8 days of aformulation of lipid-conjugated polyamide (Compound 23)/DNA complex,prepared by the “dilution-concentration” formulation method.

FIG. 9 shows particle size stability over a period of 8 days of aformulation of lipid-conjugated polyamide (Compound 16)/DNA complex,prepared by the “dilution-concentration” formulation method.

FIG. 10 shows particle size stability over a period of 8 days of aformulation of lipid-conjugated polyamide (Compound 23)/DNA complex,prepared by the “dilution-concentration” formulation method.

FIG. 11 illustrates the stability of a formulation of lipid-conjugatedpolyamide (Compound 16)/DNA complex prepared by the“dilution-concentration” formulation method and a formulation ofDMRIE-C™/DNA complex prepared by a conventional formulation method. HTI080 cells were transfected with lipid-conjugated polyamide/DNA complex 2days postformulation and with DMRIE-C™/DNA complex immediately afterformulation. Results are shown for transfected cells cultured in bothFCS-supplemented and OptiMEM media.

FIG. 12 illustrates the stability of a formulation of lipid-conjugatedpolyamide (Compound 16)/DNA complex prepared by the“dilution-concentration” formulation method and a formulation ofDMRIE-C™/DNA complex prepared by a conventional formulation method.HT1080 cells were transfected with lipid-conjugated polyamide/DNAcomplex 18 days postformulation and with DMRIE-C™/DNA compleximmediately after formulation. Results are shown for transfected cellscultured in both FCS-supplemented and OptiMEM media.

FIG. 13 illustrates the stability of a formulation of lipid-conjugatedpolyamide (Compound 23)/DNA complex prepared by the“dilution-concentration” formulation method and a formulation ofDMRIE-C™/DNA complex prepared by a conventional formulation method.HT1080 cells were transfected with lipid-conjugated polyamide/DNAcomplex 4 days postformulation and with DMRIE-C™/DNA complex immediatelyafter formulation. Results are shown for transfected cells cultured inboth FCS-supplemented and OptiMEM media.

FIG. 14 illustrates the stability of a formulation of lipid-conjugatedpolyamide (Compound 23)/DNA complex prepared by the“dilution-concentration” formulation method and a formulation ofDMRIE-C™/DNA complex prepared by a conventional formulation method.HT1080 cells were transfected with lipid-conjugated polyamide/DNAcomplex 12 days postformulation and with DMRIE-C™/DNA compleximmediately after formulation. Also shown are the effects of doublingthe quantity of transfection medium on transfection efficiency. Resultsare shown for transfected cells cultured in both FCS-supplemented andOptiMEM media.

FIG. 15 illustrates transfection efficiency using conventional and“dilution-concentration” formulation methods. “Mixing” refers to aconventional formulation method (in which the delivery vehicle and DNAwere mixed immediately prior to transfection). “Preformed” refers toformulation of delivery vehicle/DNA complexes by the“dilution-concentration” formulation method, followed by transfection 1to 5 days later. Also shown is cell toxicity. Results are shown fortransfected cells cultured in FCS-supplemented medium.

GENERAL METHODS AND DETAILED DESCRIPTION

The terms “lipid-conjugated polyamide compound” and “lipid-conjugatedcompound” are used interchangeably herein to refer to a compounds of thepresent invention which have both an oligomeric amide moiety and one ormore lipid moieties.

The terms “oligomeric” and “oligomeric amide” are used interchangeablyherein to refer to two or more monomer units that are linked together byan amide bond,

The term “monomer” or “monomeric” unit refers to the unit defined by theformula

As used herein, the term “lipid” refers to a hydrophobic or amphipathicmoiety. A lipid moiety can be conjugated directly to the oligomericamide moiety, or optionally, indirectly to the oligomeric amide moietyvia a linker moiety.

The terms “oligomeric reactant,” “oligomer reactant,” and “oligomericamide reactant,” and “lipid reactant” refer herein to reactive speciesfrom which lipid-conjugated polyamide compounds of the present inventionare synthesized.

The term “backbone” refers herein to the scaffold structure of a moietywhich is typically either a straight chain, branched or cyclicarrangement of covalently bonded carbon or heteroatoms (i.e., thescaffold structure does not include any of the hydrogen atoms, oralternatively, substitution groups bonded to it).

As used herein, the term “optionally substituted” refers to thereplacement of hydrogen with a monovalent radical, such as, for example,hydroxyl-, carboxyl-, phospho-, amino-, halo-, alkyl-, aryl-,arylalkyl-, thioamido-, amido-, nitro-, cyano-, haloalkyl-, and thelike.

The term “aliphatic” refers herein to straight chain, branched andcyclic compounds that do not have aromatic properties, which containcarbon atoms and optionally, one or more heteroatoms (i.e., one or morefuinctional groups, such as, for example, a substituted amino, analkoxy, a carbonyl, an ester, and the like), and optionally one or moredouble or triple bond (i.e., alkenyl or alkynyl, respectively).

As used herein, the term “aryl” refers to aromatic groups, such as, forexample, monocyclic and polycyclic aromatic groups, having one or moreheteroatoms incorporated therein (e.g., nitrogen, oxygen, sulfur, andphosphorus). The term “polycyclic” refers herein to both fused andnon-fused cyclic structure in which at least one cyclic structure isaromatic. Exemplary aryl moieties include, phenyl, naphthyl, and thelike.

The term “arylalkyl” refers herein to an alkyl group, having optionalfunctional groups incorporated therein, substituted with an aryl group.Exemplary arylalkyl moieties include benzyl, picolyl, and the like.

As used herein, the term “delivery vehicle” refers to a compound and/orstructure that complexes with and facilitates the delivery of abiologically active compound to a target site. Suitable deliveryvehicles employed in the practice of the present invention include, forexample, lipid-conjugated polyamide compounds of the present invention,lipids, polycationic non-lipid compounds, liposomes, and the like.

As used herein, the term “complex” refers to a structure formed byinteraction between two or more compounds or structures. Suchinteraction can be via chemical interaction, such as, for example,covalent, ionic, or secondary bonding (e.g., hydrogen bonding), and thelike, or via physical interaction, such as, for example, encapsulation,entrapment, and the like.

For example, lipid-conjugated polyamide compounds of the presentinvention can be complexed to a low molecular weight biologically activecompound (including for example, oligonucleotides) via covalent bondingthrough an intermediately positioned sequence of amino acids that issusceptible to degradation by endogenous proteolytic enzymes. Thus, forexample, exposure of the complex to degradative enzymes results incleavage and subsequent release of the biologically active compound fromthe complex. Lipid-conjugated polyamide compounds of the presentinvention can also be complexed to biologically active compounds, suchas polynucleotides, via ionic or secondary bonding, or alternatively viaencapsulation or entrapment.

The terms “polynucleotide” and “polynucleic acid” are usedinterchangeably herein to refer to DNA, RNA, and analogues thereof,peptide-nucleic acids, as well as DNA or RNA having non-phosphatecontaining nucleotides. Polynucleotides employed in the practice of thepresent invention can be single-stranded, double-stranded, or chimericsingle- or double-stranded molecules.

All publications mentioned herein are incorporated herein by referencefor the purpose of disclosing and describing features of the inventionfor which the publications are cited in connection with.

LIPID-CONJUGATED POLYAMIDE COMPOUNDS

The present invention provides lipid-conjugated polyamide compoundshaving the general formula:

wherein n is an integer selected from 1 to about 48 and m is an integerselected from about 2 to about 48,

wherein R₁ for each monomeric unit,

and R_(a) are independently selected from the group consisting of ahydrogen atom; a hydroxy group; an amino group; a carboxyl group; asulfonyl group; -SH; an optionally substituted, branched or straightchain aliphatic group having 1 to about 8 carbon atoms in a backbonestructure that optionally contains nitrogen, oxygen, sulfur, andphosphorus, wherein said aliphatic group optionally has one or moredouble or triple bonds; an optionally substituted aryl group having fromabout 3 to about 12 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfur, and phosphorus; an optionallysubstituted arylalkyl group having from about 3 to about 12 carbon atomsin a backbone structure that optionally contains nitrogen, oxygen,sulfur, and phosphorus, wherein the alkyl component of said arylalkyloptionally has one or more double or triple bonds; and a lipid moietythat is optionally bonded to linker moiety,

wherein R₁ is not a hydrogen atom for at least one monomeric unit,

wherein R_(c) is selected from a hydrogen atom; a hydroxy group; anamino group; a hydrazine group; a sulfonyl group; —SH; an optionallysubstituted, branched or straight chain aliphatic group having 1 toabout 8 carbon atoms in a backbone structure that optionally containsnitrogen, oxygen, sulfur, and phosphorus, wherein said aliphatic groupoptionally has one or more double or triple bonds; an optionallysubstituted aryl group having from about 3 to about 12 carbon atoms in abackbone structure that optionally contains nitrogen, oxygen, sulfur,and phosphorus; an optionally substituted arylalkyl group having fromabout 3 to about 12 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfuir, and phosphorus, wherein the alkylgroup of said arylalkyl optionally has one or more double or triplebonds; and a lipid moiety that is optionally bonded to a linker moiety,

wherein when R₁, R_(a), or R_(c) is an aryl or arylalkyl group havingfewer than about 5 carbon atoms in a backbone structure, said backbonestructure further comprises one or more heteroatoms, such as, forexample, oxygen and/or nitrogen,

wherein W for each monomeric unit is independently selected from anoptionally substituted, branched or straight chain divalent moietyhaving from 1 to about 50 atoms and optionally, one or more double ortriple bonds in a backbone that contains carbon and optionally containsnitrogen, oxygen, sulfur, and phosphorus, wherein said optionalsubstitution of W may be a lipid moiety that is optionally bonded to alinker moiety,

wherein said lipid moiety is a hydrophobic or amphipathic moietyselected from the group consisting of:

(i) optionally substituted aryl or arylalkyl moieties having from about14 to about 50 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfur, and phosphorus, wherein the alkylgroup of said arylalkyl optionally has one or more double or triplebonds; and

(ii) optionally substituted, branched or straight chain aliphaticmoieties having from about 10 to about 50 carbon atoms in a backbonestructure that optionally contains nitrogen, oxygen, sulfur, andphosphorus, wherein said aliphatic moieties optionally have one or moredouble or triple bonds, and

wherein at least one of R_(a), R_(c), W for a single monomeric unit, andR₁ for a single monomeric unit comprises a lipid moiety.

Lipid-conjugated polyamides of the present invention can be randompolymers where each R₁ and W varies from monomer to monomer (e.g., wheren is 1 and m is an integer from about 2 to about 48). Alternatively, thelipid-conjugated polyamides can be polymers having m number of n-mers(i.e., where n is greater than 1 and m is an integer from about 2 toabout 48) that are either repeating (i.e., each n-mer is the same) orrandomly variable (i.e., the monomer composition of each n-mer variesfrom n-mer to n-mer).

Typically, the integer n is not more than about 40, more typically notmore than about 20, and even more typically not more than about 6.Preferably, n is about 3. The integer m is typically not more than about40, more typically not more than about 25. Usually, the integer m is notmore than about 15, typically not more than about 12, and even moretypically not more than about 8.

Heteroatoms (i.e., nitrogen, oxygen, sulfur, and phosphorus)incorporated into the backbone structure of aliphatic moieties and thealkyl component of arylalkyl moieties typically form a functional group,such as, for example, a substituted amine, a carbonyl, an alkoxy, anester, and the like. Thus, aliphatic and arylalkyl moieties employed incompounds of the present invention optionally have one or morefunctional groups incorporated therein. Heteroatoms incorporated intothe backbone structure of aryl moieties are incorporated as ring atomsin cyclic aryl moieties.

When R₁, R_(a), and R_(c) are aliphatic, they typically contain at least2 carbon atoms in a backbone structure and more typically contain atleast about 3 carbon atoms in a backbone structure. Aryl and arylalkylR₁, R_(a), and R_(c) groups can be linear or cyclic. Aryl and arylalkylR₁, R_(a), and R_(c) having less than about 5 carbon atoms in a backbonestructure, also typically have one or more heteroatoms in the backbonestructure, such as, for example, nitrogen and/or oxygen. Typically aryland arylalkyl R₁, R_(a), and R_(c) have at least about 5 carbon atoms ina backbone structure.

R_(a) is typically —OH, —H, —SH, —COOH, sulfonyl, or a lipid moietyoptionally conjugated to a linker moiety. Rc is typically —OH, —H, —SH,—NH₂, sulfonyl, hydrazine, or a lipid moiety optionally conjugated to alinker moiety. Preferably, either R_(a) or R_(c) a is a lipid moietyoptionally conjugated to a linker moiety.

R₁ can be a sidechain that is cationic, anionic, or neutral atphysiological relevant pH. Typically, physiological pH is at least about5.5 and typically at least about 6.0. More typically, physiological pHis at least about 6.5. Usually, physiological pH is less than about 8.5and typically less than about 8.0. More typically, physiological pH isless than about 7.5.

Suitable cationic sidechains include, for example, arninoalkyl (e.g.,aminoethyl, aminopropyl, aminobutyl, aminopentyl, and the like) as wellas derivatives thereof; (S)-α-methylethylenediamino and derivativesthereof; trimethylaminoethyl and derivatives thereof; guanidinoalkyl(e.g., guanidinoethyl, guanidinopropyl, guanidinobutyl, guanidinopentyl,and the like) and derivatives thereof; aminobenzyl and derivativesthereof; pyridinium and derivatives thereof; and other like cationicmoieties that are known to those of ordinary skill in the art.

Suitable neutral sidechains include, for example, (S) or(R)-α-methylbenzyl and derivatives thereof; benzyl and derivativesthereof; phenethyl and derivatives thereof; naphthylmethyl andderivatives thereof; (S) or (R)-α-methylnaphthyl and derivativesthereof; N-propylpyrrolidinone and derivatives thereof; cyclohexylmethyland derivatives thereof; furfuryl and derivatives thereof;3,4,5-trimethoxybenzyl and derivatives thereof; methoxyethyl andderivatives thereof; p-methoxyphenethyl and derivatives thereof;isoarnyl (“IsoA”) and derivatives thereof; and other like neutralmoieties that are known to those of ordinary skill in the art.

Suitable anionic sidechains include, for example, carboxy methyl,carboxy ethyl, and the like, and derivatives thereof; benzoic acid andderivatives thereof; phosphates and derivatives thereof; sulfates andderivatives thereof; and other like anionic moieties that are known tothose of ordinary skill in the art.

Optionally, R₁ can be a moiety found on naturally- ornon-naturally-occuring amino acids, or R₁ can be a lipid moietyoptionally bonded to a linker moiety. As used herein, the term“naturally-occuring amino acid” refers to Ala, Cys, Asp, Glu, Phe, His,Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr. The term“non-naturally-occuring amino acid” refers to amino acids typically notfound in nature, including, for example, D-isomers of naturally-occuringamino acids, 2-aminoadipic acid, 2-aminobutyric acid, norvaline,norleucine, ornithine, and the like.

Typically R₁ is not hydrogen for at least two monomeric units, moretypically R₁ is not hydrogen for at least three monomeric units if n×mis 3 or more. Typically, less than about 75% of the monomer units havean R₁ that is hydrogen. More typically, less than about 50% of themonomer units have an R₁ that is hydrogen. Even more typically, lessthan about 25% of the monomer units have an R₁ that is hydrogen. Evenmore typically R₁ is not hydrogen for any of the monomeric units.

W is typically

where R₂ and R₃ for each monomeric unit are monovalent moietiesindependently selected from a hydrogen atom; a hydroxy group; an aminogroup; a carboxyl group; a sulfonyl group; —SH; an optionallysubstituted, branched or straight chain aliphatic group having from 1 toabout 8 carbon atoms in a backbone structure that optionally containsnitrogen, oxygen, sulfur, phosphorus, and the like, wherein saidaliphatic group optionally has one or more double or triple bonds; anoptionally substituted aryl group having from about 3 to about 12 carbonatoms in a backbone structure that optionally contains nitrogen, oxygen,sulfur, phosphorus, and the like; an optionally substituted arylalkylgroup having from about 3 to about 12 carbon atoms in a backbonestructure that optionally contains nitrogen, oxygen, sulfur, phosphorus,and the like, wherein the alkyl component of said arylalkyl optionallyhas one or more double or triple bonds; and a lipid moiety that isoptionally bonded to a linker moiety,

wherein when either R₂ and R₃ is an aryl or arylalkyl group having fewerthan about 5 carbon atoms in a backbone structure, the backbonestructure typically comprises one or more heteroatoms, such as, forexample, oxygen and/or nitrogen.

When R₂ and R₃ are aliphatic, they typically contain at least 2 carbonatoms in a backbone structure and more typically contain at least about3 carbon atoms in a backbone structure. Aryl and arylalkyl R₂ and R₃groups can be linear or cyclic. Aryl and arylalkyl R₂ and R₃ having lessthan about 5 carbon atoms in a backbone structure, also typically haveone or more heteroatoms in the backbone structure, such as, for example,nitrogen and/or oxygen. Typically aryl and arylalkyl R₂ and R₃ have atleast about 5 carbon atoms in a backbone structure.

R₂ and R₃ typically are moieties found on naturally-occuring andnon-naturally-occuring amino acids. Usually, at least one of R₂ and R₃is a hydrogen atom. Most typically, R₂ and R₃ are both hydrogen for allmonomeric units, such that compound (I) is a lipid-conjugated,N-substituted polyglycine compound.

The lipid moiety can be positioned at R_(a), R_(c), R₁ for one or moremonomers, or at a substitution position in W for one or more monomers.Lipid moieties can be bonded directly to a monomeric unit, or they canbe bonded indirectly to a monomeric unit via a linker moiety.

The term “linker” used herein refers to a moiety that finctions tocouple the oligomeric amide and lipid moieties together in a manner suchthat the molecular distance between the two moieties is greater thanwould be if the lipid and oligomeric amide moieties were coupleddirectly to each other. Linker moieties can be relatively small, havingfrom 1 to about 20 atoms in a backbone, or alternatively polymeric.Small linker moieties are optionally substituted and typically have from1 to about 20 atoms in a backbone (e.g., carbon, nitrogen, oxygen,sulfur, phosphorus, and the like). Typically, small linker moities haveless than about 18 atoms in a backbone, and more typically, less thanabout 15 atoms in a backbone. Usually, small linker moieties have lessthan about 10 atoms in a backbone, and optionally have less than about 5atoms in a backbone.

Linker moieties can be derived from bifinctional molecules such as, forexample, 6-aminohexanoic acid, 2-(2-(2-aminoethoxy)ethoxy)ethoxy) aceticacid, and the like) that are capable of reacting with both oligomericand lipid reactants. Linker moieties also can be derived from groupssuch as, for example, acyl and substituted-acyl groups, sulfonyl andsubstituted-sulfonyl groups, and other like reactive moieties that areemployed during chemical synthesis to facilitate conjugation of thelipid moiety to the oligomeric moiety.

Polymeric linker moieties are optionally substituted (e.g., hydroxy-,carboxy-, phospho-, amino-, and the like), substantially linear polymershaving a backbone that contains carbon, and optionally containsnitrogen, oxygen, sulfur, phosphorus, and the like. Polymeric linkermoieties have an average molecular weight between about 300 daltons andabout 15,000 daltons, typically less than about 10,000 daltons, moretypically less than about 5,000 daltons, and even more typically lessthan about 3000 daltons, and optionally less than about 1000 daltons.Suitable polymeric linker moieties include, for example, polyethyleneglycols, polypropylene glycols, polyvinyl alcohols,polyvinylpyrrolidones, and the like.

Lipid moieties are hydrophobic moieties or amphipathic moieties that areeither neutral (i.e., having no charge or a net charge of zero) orcharged, and either naturally or synthetically derived. Typically, thelipid moiety in lipid-conjugated polyamide compounds of the presentinvention is amphipathic.

Suitable lipid moities include: (1) optionally substituted, aryl orarylalkyl moities having from about 14 to about 50 carbon atoms in abackbone structure that optionally contains nitrogen, oxygen, sulfur,phosphorus, and the like, where the alkyl component of the arylalkylmoiety optionally has one or more double or triple bonds; (2) optionallysubstituted, branched or straight chain aliphatic moieties having fromabout 10 to about 50 carbon atoms in a backbone structure thatoptionally contains nitrogen, oxygen, sulfur, phosphorus, and the like,and optionally has one or more double or triple bonds.

Typically, aryl and arylalkyl lipid moieties have at least about 16carbon atoms and more typically have at least about 20 carbon atoms, andeven more typically at least about 30 carbon atoms.

Aliphatic lipid moities employed in compounds of the present inventiontypically have at least about 12 carbon atoms and more typically have atleast about 14 carbon atoms. Usually, the aliphatic lipid moieties haveat least about 18 carbon atoms, more usually at least about 24 carbonatoms, and even more usually at least about 30 carbon atoms.

The number of lipid moieties in lipid-conjugated polyamide compounds ofthe present invention can vary depending on the degree of hydrophobicitydesired, and will also vary with oligomer length (i.e., n×m) and size oflipid moiety. For example, when the lipid moiety has about 30 carbonatoms or less, lipid-conjugated polyamide compounds of the presentinvention typically have conjugated to it, a number of lipid moitiesthat is less than the number computed as 90% of the total number ofmonomeric groups (i.e., n×m) (i.e., if n is 3 and m is 3, then thenumber of lipid moieties conjugated to the lipid-conjugated polyamidecompound is typically less than about 8). More typically, when the lipidmoiety has about 30 carbon atoms or less, lipid-conjugated polyamidecompounds of the present invention have conjugated to it, a number oflipid moieties that is less than about 80% of the total number ofmonomeric groups, more typically less than about 75% of the total numberof monomeric groups, and even more typically less than about 60% of thetotal number of monomeric groups.

When the lipid moiety has more than about 30 carbon atoms, typically,lipid-conjugated polyamide compounds of the present invention haveconjugated to it a number of lipid moities that is less than the numbercomputed as 50% of the total number of monomeric groups.

Suitable lipid moieties include those having one or more hydrophobictails that are optionally substituted aliphatic, straight chainmoieties, each hydrophobic tail independently having from about 8 toabout 30 carbon atoms in a backbone that in addition, optionallycontains nitrogen, oxygen, sulfur, phosphorus, and the like. Typically,hydrophobic tails have at least about 10 carbon atoms in a backbone andmore typically have at least about 12 carbon atoms in a backbone.Hydrophobic tails employed in lipid-conjugated polyamide compounds ofthe present invention typically do not have more than about 26 carbonatoms in a backbone, and more typically do not have more than about 24carbon atoms in a backbone.

Natural lipid moieties employed in the practice of the present inventioncan be derived from, for example, phospholipids, including, for example,phosphoglycerides (including both acyl phosphoglycerides (such as, forexample, phosphatidic acid, phosphatidyl ethanolamine, phosphatidylserine, phosphatidyl inositol, phosphatidyl inositol phosphate,phosphatidyl inositol bisphosphate, phosphatidyl glycerol,diphosphatidylglycerol, and the like) and ether phosphoglycerides);glycosylglycerides (such as, for example, monogalactosyl diacylglycerol,digalactosyldiacylglycerol, sulphoquinovosyldiacylglycerol,dimannosyldiacylglycerol, galactofuranosyldiacylglycerol,galactosylglucosyldiacylglycerol, galactosylglucosyldiacylglycerol,glucosylgalactosylglucosyldiacylglycerol, and the like); sphingolipids(such as, for example, sphingosines, glycosyl ceramides, gangliosides,and the like); and saturated and unsaturated sterols (such as, forexample, cholesterol, ergosterol, stigmasterol, sitosterol, and thelike); and other like natural lipids.

Suitable synthetic lipid moieties can be derived from, for example,dipalmitoyl phosphotidylethanolamine (DMPE) (Genzyme Corp., Cambridge),DMRIE-C™ (GibcoBRL, Gaithersburg, Md.),2,3-dioleyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate(DOSPA) (Lipofectamine™ , GibcoBRL, Gaithersburg, Md.),3β-[N-(N′,N′-dimetylaminoethyl)carbamoyl]cholesterol, Tfx-50 (PromegaCorp., Madison, Wiss.),N,N1,N2,N3-tetramethyl-N,N1,N2,N3-tetrapalmitylsperimine (TM-TPS)(Cellfectin, GibcoBRL, Gaithersburg, Md.), dipalmitoylphosphatidylethanolaminospermine, and the like.

Suitable lipid moieties also include those derived from fatty acids andfatty alcohols having from about 8 to about 24 carbon atoms in abackbone. Typically, the fatty acids and fatty alcohols have at leastabout 10 carbon atoms in a backbone, and more typically have at leastabout 12 carbon atoms in a backbone. Usually, the fatty acids andalcohols from which lipid moieties are derived have less than about 20carbon atoms in a backbone.

Typically, R_(a) is a lipid moiety or a lipid moiety conjugated to alinker moiety. A particularly useful lipid moiety-containing R_(a)radical is the phosphatidyl alkylamino-substituted acyl radical havingthe formula,

where p is an integer selected from 2 or 3, and each R₄ is independentlyselected from an alkyl or alkenyl moiety having from about 6 and toabout 25 carbon atoms in a backbone. Typically R₄ has up to about 22carbon atoms in a backbone, more typically, up to about 20 carbon atoms,even more typically up to about 18 atoms. Typically, R₄ has at leastabout 8 carbon atoms in a backbone, more typically at least about 10carbon atoms, and even more typically at least about 12 carbon atoms ina backbone. Exemplary R₄ moieties include dodecyl, tridecyl, tetradecyl,pentadecyl, hexadecyl, heptadecyl, octadecyl, and the like. Preferably pis 2.

Lipid-conjugated polyamide compounds of the present invention can beoptionally further conjugated or complexed with agents that impart, forexample, targeting capabilities, structural features, biologicalactivity, or that introduce degradations sites, and the like. Suitableagents include, for example, mono-, di-, and polysaccaharides,polyethylene glycols, amino acids, peptides, polypeptides, proteins(including, for example, lipoproteins, glycoproteins, antibodies, andthe like), crosslinking agents, marker agents (such as, for example,fluoroscein, biotin, ³²P, and the like), and the like.

Those of ordinary skill in the art will appreciate that R₁, R_(c),R_(a), W, and the particular lipid moiety employed can be readily variedto optimize the physicochemical properties of the lipid-conjugatedpolyamide compound for delivery of a particular type of biologicallyactive compound. For example, oligomeric moieties of the presentinvention suitable for use in the delivery of polynucleic acids to cellshave a net positive charge and are capable of condensing polynucleicacids so that they are more compact in size, thus facilitating theirdelivery to cells.

Compounds of formula (I) that are suitable for use in the delivery ofpolynucleic acids to cells, include lipid-conjugated polyamide compoundshaving repeating n-mer units (i.e., where n is greater than 1). Forexample, when n is 3, the lipid-conjugated polyamide compound of formula(I) has repeating trimer units, i.e.,

where R_(a), R_(c), m, each W and each R₁ are defined as in formula (I).Compounds having formula (IV) that are suitable for use in the deliveryof polynucleic acids to cells include, for example, those where R₁ ¹ isa cationic side chain, R₁ ² and R₁ ³ are both neutral side chains, eachW is CH₂, R_(a) is NH₂, and R_(a) is defined by formula (III), such asthose compounds shown in Table 2, in Example 1, herein.

Lipid-conjugated polyamide compounds of the present invention typicallyform concentration-dependent, ordered two- or three-dimensionalstructures in solution. Such structures include two dimensional arrays,such as, for example, a single charged layer or a lipid bilayer surface,and three-dimensional structures, such as, for example, micelles,vesicles, and liposomes. Typically, ordered structures formed fromlipid-conjugated polyamide compounds of the present invention bythemselves, typically are sufficiently small such that they do notscatter light. Micelles, vesicles, and liposomes prepared fromlipid-conjugated compounds complexed with polynucleotides typically haveaverage particle sizes that are less than about 1 μm, more typicallyless than about 500 nm, and even more typically less than about 200 nm.

In addition to the delivery of biologically active agents to cells,lipid-conjugated polyamide compounds of the present invention can alsobe used in applications, such as, for example, screening peptide-likecompounds for biological activity, incorporation into biosensors suchthat the oligomeric moiety has the capacity to bind to a target ligand,and the like. For drug screening applications, for example, libraries oflipid-conjugated polyamnide compounds having a variety of R₁ groups canbe synthesized and subsequently screened for biological activity inaccordance with the methods for synthesizing and screening modifiedpeptide libraries described in PCT publication WO 91/19735 (publishedDec. 26, 1991), incorporated herein by reference.

SYNTHESIS OF LIPID-CONJUGATED POLYAMIDE COMPOUNDS

Lipid-conjugated polyamide compounds of the present invention can besynthesized by both solid-phase and solution-phase methods. The presentinvention also provides a method of synthesizing lipid-conjugatedpolyamide compounds, said method comprising:

a) contacting

(1) a lipid reactant, with

(2) an oligomer reactant, wherein said oligomer reactant has the generalformula:

 wherein n is an integer selected from 1 to about 48, and m is aninteger from about 2 to about 48,

wherein each T_(a) and T_(c), is independently selected from a terminalgroup and a reactive moiety that is capable of further reaction withsaid lipid reactant,

wherein R₁ for each monomeric unit,

in said oligomer reactant is selected from the group consisting of ahydrogen atom; a hydroxy group; an amino group; a carboxyl group; asulfonyl group, —SH; an optionally substituted, branched or straightchain aliphatic group having from 1 to about 8 carbon atoms in abackbone structure that optionally contains nitrogen, oxygen, sulfur,and phosphorus, wherein the aliphatic group optionally has one or moredouble or triple bonds; an optionally substituted aryl group having fromabout 3 to about 12 carbon atoms in a backbone structure that optionallycontains nitrogen, oxygen, sulfur, and phosphorus; an optionallysubstituted arylalkyl group having from about 3 to about 12 carbon atomsin a backbone structure that optionally contains nitrogen, oxygen,sulfur, and phosphorus, wherein the alkyl component of said arylalkyloptionally has one or more double or triple bonds; and a reactive moietythat is capable of further reaction with said lipid reactant,

wherein when R₁, R_(a), or R_(c) is an aryl or arylalkyl group havingfewer than about 5 carbon atoms in a backbone structure, the backbonestructure typically comprises one or more heteroatoms, such as, forexample, oxygen and/or nitrogen,

wherein R₁ is not a hydrogen atom for at least one monomeric unit,

wherein W for each monomeric unit is selected from an optionallysubstituted, branched or straight chain divalent moiety having from 1 toabout 50 atoms in a backbone that contains carbon, and optionallycontains nitrogen, oxygen, sulfur, and phosphorus, and optionally one ormore double or triple bonds, wherein said optional substitution of W maybe a reactive moiety that is capable of further reaction with said lipidreactant,

wherein at least one of T_(a), T_(c), W for a single monomeric unit, orR₁ for a single monomeric unit comprises a reactive moiety that iscapable of further reaction with said lipid reactant; then

b) reacting said lipid reactant with said oligomer reactant to conjugatethe lipid reactant to the oligomer reactant.

The term “lipid reactant” used herein refers to a reactive specieshaving a lipid moiety that is capable of participating in a chemicalreaction, such as, for example, nucleophilic displacement, condensation,and the like. Lipid reactants having functional groups, such as, forexample, —NH₂, —COOH, —SH, —OH, —SO₂Cl, and —CHO are particularly usefulfor synthesizing lipid-conjugated compounds of the present invention.Lipid reactants suitable for use in the practice of the presentinvention include lipid reactants having any one of the lipid moietiesdescribed herein which can react with, or which can be modified to reactwith, the oligomeric reactant or a linker. Typically, lipid reactantsare primary, secondary, or tertiary amines. Preferred lipid reactantsare phosphatidylethanolamines.

As used herein, the term “oligomer reactant” refers to an oligomericamide that is capable of participating in a chemical reaction, such as,for example, nucleophilic displacement, condensation, and the like.Oligomer reactants typically are acylated with a leaving group that issusceptible to nucleophilic displacement by a nucleophile, such as anamine. Oligomer reactants suitable for use in the practice of thepresent invention include all of the oligomeric amide substituentsdescribed for formula (I) (i.e.,

herein.

As used herein, the term “reactive moiety” refers to a moiety that iscapable of participating in a reaction with the lipid reactant. Typicalreactive moieties include, for example, —NH₂, —OH, —H, —SH, —COOH, acyl(e.g., acetyl), benzoyl, sulfonyl (e.g., dansyl), amide, hydrazine(typically a T_(c) group), and derivatives thereof (includingalkyl-substituted derivatives), and the like. Typically, the reactivemoiety is an acyl moiety substituted with a leaving group that issusceptible to nucleophilic displacement by a nucleophile, such as anamnine.

Exemplary terminal groups include R_(a) and R_(c) moieties that are notreactive moieties, moieties that are biologically active agents,targeting agents (e.g., a cell receptor ligand, antibody, etc.), markeragents, amino acid residues that function, for example, as a degradationsite for endogenous proteolytic enzymes, and the like. These terminalgroups typically are not further reactive with the lipid reactant.

The oligomer reactant and lipid reactant can be optionally bonded toeach other via a linker moiety (which optionally can be derived from areactive moiety). Alternatively, the linker moiety, which is derivedfrom a molecule that is capable of reacting with both oligomeric andlipid reactants, can be optionally conjugated to either the lipid oroligomer reactant prior to reaction between lipid and oligomerreactants. Thus, the lipid reactant can be conjugated to the oligomerreactant either directly, or indirectly via the linker moiety.

The term “reacting” used herein refers to one or more chemical reactionsthat result in formation of a chemical bond between the lipid reactantand the oligomer reactant, either directly, or indirectly via the linkermoiety. Suitable reactions include, for example, condensation (e.g.,acylation, and the like) and nucleophilic displacement.

Oligomer reactants having the general formula (IV) can be prepared, forexample, via a series of nucleophilic displacement reactions accordingto the solid-phase method described by Zuckermann et al., PCT WO94/06451(published Mar. 31, 1994), incorporated herein by reference. The methodcan be performed utilizing automated peptide synthesis instrumentationto permit rapid synthesis of oligomer reactants of interest. Theseinstruments are commercially available from, for example, AppliedBiosystems.

Specifically, monomer assembly into oligomer reactants is achieved bythe sequential addition of “submonomer” units to the growing chain. Inone method of monomer assembly, each cycle of monomer addition consistsof two steps:

(1) acylation of a secondary amine bound to the solid support with anacylating agent that has a leaving group (i.e., a group susceptible tonucleophilic displacement by a nucleophile, such as an amine) and acarbonyl group (e.g., a carboxyl group) (i.e., the “acylation step”);followed by

(2) nucleophilic displacement of the leaving group with a sufficientamount of a submonomer that has a primary, secondary, or tertiary aminogroup to introduce a side-chain (i.e., the “nucleophilic displacementstep”).

A schematic of the reaction scheme is shown in FIG. 1. Exemplaryacylating agents include haloacetic acid, halomethyl benzoic acid, andthe like. The efficiency of displacement of the leaving group ismodulated by the type of acylating agent employed. For example, when ahaloacetic acid is employed, it has been observed that iodine is moreefficient at displacing the leaving group compared to chlorine. Suitablesubmonomers include alkylamines, alkenylamines, aromatic amines,alkoxyamines, semicarbazides, acyl hydrazides, and derivatives thereof,and the like.

Oligomer synthesis using the submonomer approach occurs in the carboxyto amino direction. The oligomer is elaborated until the desired length,then is terminated, for example, with a bromoacetamide group. Oneadvantage of using solid phase submonomer assembly to construct oligomerreactants of the present invention is that the need for N-α-protectedmonomers is eliminated, as only reactive side-chain fimctionalities needto be protected.

Typically, the oligomeric reactant is synthesized as a series ofrepeating di-, tri-, or tetra-mer units. An exemplary trimer-basedcationic oligomer has the following monomer sequence in the aminoterminal (T_(a)) to carboxy terminus (T_(c)) direction:

(1) positively charge monomer

(2) neutral monomer, and

(3) neutral monomer.

The terms “neutral monomer” and “positively charged monomer” as usedherein refer to the net charge of the monomeric unit.

Further reaction of the oligomer reactant with the lipid reactant canoccur by further acylation and/or nucleophilic displacement. Forexample, an oligomer reactant that is haloacylated (e.g., where T_(a) isa bromoacetyl group) can be reacted with an lipid reactant that is aprimary, secondary, or tertiary amine. Conjugation thus occurs bynucleophilic displacement of the bromine, to form a lipid-conjugatedpolyamide compound.

LIPID-CONJUGATED POLYAMIDE COMPOSITIONS AND USES THEREOF

In yet another embodiment, the present invention provides compositionscomprising lipid-conjugated polyamide compound(s) of the presentinvention and an effective amount of a biologically active agent. Asused herein, the terms “effective amount” and “effective dose” refer toan amount of biologically active agent or biologically activeagent-containing lipid-conjugated polyamide composition of the presentinvention that is sufficient to detectably induce, or participate in, abiological response, such as, for example, signal transduction,transcription, translation, lymphocyte activation, including, forexample, antibody production, and the like, in for example, a cell, amammal, or a bird. The term “biologically active agent” used hereinrefers to an agent that upon administration in an effective amount to,for example, a cell, a mammal, or a bird, induces or participates in, abiological response.

When the biologically active agent is a polynucleotide, the relativequantities of lipid-conjugated polyamide compound to polynucleic acidare typically selected such that the +/− charge ratio oflipid-conjugated polyamide compound to polynucleotide in the compositionis at least about 2 and less than about 10. More typically, the +/−charge ratio is less than about 8, and even more typically is less thanabout 4. The charge ratio is computed according to the following:

Charge Ratio=(n_(L)×M_(L))/(3.03×M_(DNA)),

where n_(L) is the number of moles of lipid-conjugated polyamidecompound, M_(L)=net number of charges/mole lipid-conjugated polyamide,and where M_(DNA)=micrograms of DNA.

Compositions of the present invention can be in liquid or solid form,and can optionally include pharmaceutically acceptable excipients. Suchexcipients can be used as fillers, processing aids, delivery enhancersand modifiers, and the like. Suitable excipients include, for example,calcium phosphate, magnesium stearate, talc, monosaccharides,dissaccharides, polysaccharides, gelatin, cellulose, methyl cellulose,sodium carboxymethyl cellulose, dextrose, polyvinyl alcohol,polyvinylpyrrolidinone, low melting waxes, ion exchange resins, and thelike, as well as combinations of any two or more thereof. A thoroughdiscussion of pharmaceutically acceptable excipients is available in“Rernington's Pharmaceutical Sciences” (Mack Pub. Co., NJ 1991), whichis incorporated herein by reference.

Additional agents can be included in the compositions, such as, forexample, marker agents, nutrients, and the like. For example, when thebiologically active agent is a polynucleotide, agents that promoteendocytosis of the desired nucleic acids or aid in binding of thenucleic acids to the cell surface, or both, can be incorporated intocompositions of the present invention.

Liquid compositions of the present invention can be in the form of asolution, suspension, or emulsion with a liquid carrier. Suitable liquidcarriers include, for example, water, saline, pharmaceuticallyacceptable organic solvent(s), pharmaceutically acceptable oils or fats,mixtures thereof, and the like. The liquid carrier may contain othersuitable pharmaceutically acceptable additives, such as solubilizers,emulsifiers, nutrients, buffers, preservatives, suspending agents,thickening agents, viscosity regulators, stabilizers, and the like.Suitable organic solvents include, for example, monohydric alcohols,such as ethanol, and polyhydric alcohols, such as glycols. Suitable oilsinclude, for example, soybean oil, coconut oil, olive oil, saffloweroil, cottonseed oil, and the like. For parenteral administration, thecarrier can also be an oily ester such as ethyl oleate, isopropylmyristate, and the like.

In yet another embodiment, the present invention provides a method forinducing the uptake of a biologically active agent by a cell, saidmethod comprising:

providing a composition comprising an effective amount of a biologicallyactive agent and a lipid-conjugated polyamide compound; then

contacting a biological sample with an effective dose of saidcomposition,

wherein said biological sample comprises a cell.

As used herein, the term “biological sample” refers to a samplecomprising one or more cells or tissue. Cells suitable for use in thepractice of the present invention include, for example, mammalian celllines available from the American Type Culture Collection (ATCC),Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK)cells, monkey kidney cells (COS), human hepatocellular carcinoma cells(e.g., Hep G2), human embryonic kidney cells, baby hamster kidney cells,mouse sertoli cells, canine kidney cells, buffalo rat liver cells, humanlung cells, human liver cells, mouse mammary tumor cells, othermammalian (including human) cells (e.g., stem cells, particularlyhemapoitic cells, lymphocytes, macrophages, dendritic cells, tumor cellsand the like), and the like.

Suitable tissue for use as samples in the present invention include, forexample, tissue derived from mammals, such as, muscle, skin, brain,lung, liver, spleen, blood, bone marrow, thymus, heart, lymph, bone,cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis,ovary, uterus, rectum, nervous system, eye, gland, connective, and thelike.

Modes of administration to a sample include, for example, ex vivoadministration to samples derived from a subject and in vitroadministration to a sample. Methods for carrying out these modes ofadministration are well known to those of ordinary skill in the art. Forexample, when the biological agent is a polynucleotide, ex vivo deliveryand reimplantation of transformed cells into a subject can be achievedas described in e.g., International Publication No. WO 93/14778(published Aug. 5, 1993), which is incorporated herein by reference.

In yet another embodiment, the present invention provides a method forinducing the uptake of a biologically active agent by a cell in vivo,said method comprising:

providing a composition comprising an effective amount of a biologicallyactive agent and a lipid-conjugated polyamide compound; then

administering an effective dose of said composition to a subject.

The present invention further provides a method of expressing a gene ina mammal, said method comprising:

administering a polynucleic acid complexed with a lipid-conjugatedpolyamide of the present invention to a mammal,

wherein said polynucleic acid is capable of finctionally expressing saidgene in said mammal, and

wherein said complex is effective at transfecting said gene into a cellin said mammal.

As used herein, the term “subject” refers to birds and mammals,including for example, rodents and humans. Direct administration to asubject can typically be accomplished by injection, eithersubcutaneously, intraperitoneally, intravenously or intramuscularly ordelivered to the interstitial space of a tissue. The compositions canalso be administered into a tumor or lesion. Other modes ofadministration include oral and pulmonary administration, suppositories,and transdermal applications, and the like, as well as administrationvia needles, and gene guns or hyposprays.

Lipid-conjugated compounds of the present invention, when combined witha biologically active agent, are effective at inducing the uptake thebiologically active agent by cells. As used herein, the term “induce”and its various grammatical equivalents, refers to effecting the uptakeof a biologically active agent by a cell. Methods used for detecting theuptake of biologically active agents by cells will vary depending on thetype of biologically active agent employed, however, those of ordinaryskill in the art will appreciate that cell uptake can be detected by avariety of known assays and histological techniques, as well as by avariety of diagnostic methods, including, for example, clinicaldiagnostic methods (e.g., alleviation of symptoms, etc.).

Typically, compounds of the present invention are effective at enhancingthe uptake the biologically active agent by cells. When uptake of abiologically active agent by a cell is enhanced, typically the uptake ofbiologically active agent by the cell is at least about 5% greater thanthe uptake of the biological agent in neat form (e.g., substantiallyfree of lipid-conjugated polyamide compound). More typically, whenuptake is enhanced, the uptake of the biologically active agent by thecell is at least about 10% greater than the uptake of the biologicallyactive agent in neat form, even more typically at least about 15%greater, and even more typically at least about 20% greater.

An effective amount of biologically active agent and likewise, aneffective dose of lipid-conjugated polyamide/biological agent containingcompositon will, of course, vary depending upon known factors such asthe pharmacodynarnic characteristics of the particular biologicallyactive agent, its mode and route of administration; the age, health, andweight of the recipient; nature and extent of symptoms; kind(s) ofconcurrent treatment, frequency of treatment, the effect desired, andthe like. However, the precise amount for a particular patient andbiologically active agent can be readily determined by routineexperimentation by a clinician of ordinary skill in the art. Thosehaving ordinary skill in the art will also appreciate that the preciseamount of lipid-conjugated compound employed in compositions of thepresent invention can be readily determined by routine screening studiesto determine the optimal ratio of lipid-conjugated polyamide compound tobiologically active agent for inducing the desired response.Compositions of lipid-conjugated polyamide compounds complexed withbiologically active agents can be administered as a single dose or inmultiple doses. Multiple doses can be administered either continuously,in intervals, or a combination of both. For purposes of the presentinvention, an effective in vivo amount will be from about 0.01 mg/kg/dayto about 50 mg/kg/day or about 0.05 mg/kg/day to about 10 mg/kg/day ofbiologically active agent.

Compositions of the present invention are particularly effective atinducing the uptake of polynucleotides into cells. Polynucleotide uptakeby cells can be detected by using protein expression assays orpolynucleotide hybridization techniques. Compositions can be screenedand optimized with respect to transfection efficiency by incorporating areporter gene into the DNA and assaying for the reporter gene productusing standard immunoassay methods or biological or enzymatic activityassays (such as, for example, a luciferase assay).

When combined with polynucleotides, lipid-conjugated polyamide compoundsare particularly effective at inhibiting nuclease-induced polynucleotidedegradation caused by nucleases present in serum, and other biologicalfluids. As a result, smaller quantities of polynucleotides can be moreefficiently administered using compositions of the present invention.

Thus, the present invention also provides a method for substantiallyinhibiting nuclease-induced polynucleotide degradation, said methodcomprising contacting a polynucleotide with a degradation-inhibitingquantity of lipid-conjugated polyamide compound, and introducing thepolynucleotide and the lipid-conjugated polyamide compound into anuclease-containing environment. Inhibition of nuclease-inducedpolynucleotide degradation can be detected by incubating a sample oflipid-conjugated polyamide protected polynucleotide and a control sampleof unprotected polynucleotide in, for example, serum, for various timeperiods, then analyzing the mixtures by gel electrophoresis to determinewhen degradation occurs (for example, when about 50% of thepolynucleotide has degraded) for the protected polynucleotide, ascompared to unprotected polynucleotide. The degree of degradation can bemonitored using known quantitation methods, such as, for example,radiolabelling and the like.

Typically, a degradation-inhibiting quantity of lipid-conjugatedpolyamide compound is the amount of lipid-conjugated polyamide compoundsufficient to substantially inhibit nuclease-induced polynucleotidedegradation of a polynucleotide for at least about 5 minutes, ascompared to unprotected (i.e., neat) polynucleotide. More typically, thequantity of lipid-conjugated polyamide compound is sufficient to inhibitnuclease-induced polynucleotide degradation for at least 10 minutes,more typically for at least about 30 minutes, more typically for atleast 60 minutes, more typically for at least 90 minutes, and even moretypically for at least 120 minutes, as compared to unprotectedpolynucleotide. Lipid-conjugated polyamide compounds of the presentinvention are effective at inhibiting nuclease-induced polynucleotidedegradation to the extent that lipid-conjugated polyamide-protectedpolynucleic acid typically exhibit less than about 80% of thedegradation exhibited by unprotected (i.e., neat) polynucleotide) duringthe same time period, more typically less than about 50%, even moretypically less than about 30%, and more typically, less than about 20%.

Compositions of lipid-conjugated polyamide compounds and polynucleicacid that are particularly effective at enhancing polynucleotide uptakeby cells are those where the lipid-conjugated polyamide compound hasformula (I), where W is CH₂, R_(a) contains a lipid moiety (preferably aphosphatidylethanolamine), n is greater than 1, and each n-mer containsboth cationic and neutral R₁ sidechain groups. This lipid-conjugatedpolyamide compound is also effective at protecting polynucleotides fromnuclease-induced degradation.

DILUTION-CONCENTRATION METHOD FOR MAKING STABLE POLYNUCLEICACID/DELIVERY VEHICLE COMPLEX PREPARATIONS

In still a further embodiment, the present invention provides a methodof making a stable preparation of a polynucleic acid complexed with adelivery vehicle, said method comprising:

a) combining a polynucleic acid with a first liquid carrier to form adilute polynucleic acid solution that is substantially precipitant-free;

b) combining a delivery vehicle-forming compound with a second liquidcarrier to form a delivery vehicle solution that is substantiallyprecipitant-free;

c) combining said dilute polynucleic acid solution with said deliveryvehicle solution to form a dilute preparation of deliveryvehicle/polynucleic acid complex; then

d) reducing the volume of said dilute preparation to form a stablepreparation of delivery vehicle/polynucleic acid complex,

wherein the concentration of polynucleic acid in said stable preparationis higher than the concentration of polynucleic acid in said dilutepolynucleic acid solution, and

wherein said stable preparation is substantially precipitant-free.

It has been discovered that when delivery vehicle/polynucleic acidcomplexes are formulated in liquid carrier in accordance with the“dilution-concentration” method of formulation, the resulting complexesare stable for relatively long periods of time with respect to particlesize and transfection efficiency. In addition, the stable preparationsare characteristically precipitant-free. Thus, unlike conventionaldelivery vehicle/polynucleic acid preparations in which equal volumes ofdilute solutions of polynucleic acid and delivery vehicle are mixedtogether just prior to transfection, stable preparations made accordingto the invention dilution-concentration method of formulation can beprepared and stored up to days prior to transfection without substantialchange in transfection efficiency. As used herein, the term“transfection efficiency” refers to the quantity or activity of proteinexpressed, or polynucleic acid synthesized, as a result ofadministration of a delivery vehicle/polynucletide complex to a cell.

Typically, the particle size distribution of deliveryvehicle/polynucleotide complexes in the stable preparations changes byless than about 40% one day after formulation by the invention method,as compared to the particle size distribution of the complexesimmediately after formulation. More typically, the particle sizedistribution of delivery vehicle/polynucleotide complexes in the stablepreparations changes by less than about 30%, more typically by less thanabout 20%, and even more typically by less than about 15%, one day afterformulation according to the concentration method of the presentinvention, as compared to the particle size distribution of thecomplexes immediately after formulation.

More typically, the particle size distribution of the deliveryvehicle/polynucleotide complexes in the stable preparations changes byless than about 40%, even more typically less than about 30%, usuallyless than 20%, and more usually less than about 15%, five to eight daysafter formulation by the invention method, as complared to the particlesize distribution of the complexes immediately after formulation.

As used herein, the term “dilute polynucleic acid solution” refers to asolution having a concentration of less than about 300 μg polynucleicacidlml. Typically, dilute polynucleic acid solutions have polynucleicacid concentrations of less than about 250 μg/ml, more typically lessthan about 150 μg/ml, and even more typically less than about 100 μg/ml.Preferably, dilute polynucleic acid solutions have polynucleic acidconcentrations of less than about 50 μg/ml.

The concentration of polynucleic acid in stable preparations of deliveryvehicle/polynucleic complex is greater than the polynucleic acidconcentration of the dilute polynucleic acid solution, and is typicallyat least about 150 μg (polynucleotide)/ml (preparation). More typically,the concentration of polynucleotide in stable preparation is at leastabout 250 μg/ml, more typically at least about 500 μg/ml, and even moretypically at least about 1 mg/ml, and even more typically at least about2 mg/ml.

The concentration of delivery vehicle-forming compound employed in thedelivery vehicle solution will vary depending on the ratio of DNA todelivery vehicle desired and the solubility properties of thedelivery-vehicle-forming compound employed. Those having ordinary skillin the art will recognize that the concentration and volume of deliveryvehicle-forming compound in second liquid carrier can be adjusted toachieve the desired target ratio of delivery vehicle to DNA.

When the delivery vehicle-forming compound is a lipid-conjugatedpolyamide of the present invention, the concentration of the deliveryvehicle solution is typically not more than about 5 mg/ml, moretypically not more than about 2.5 mg/ml, and typically at least about1.25 mg/ml. The volumes of delivery vehicle solution and dilutepolynucleic acid solution combined are preferably selected such that theratio of lipid-conjugated polyamide to polynucleic acid is about 5 mglipid-conjugated polyamide to about 1 mg polynucleic acid. Thus, forexample, if a 5 mg/ml lipid-conjugated polyamide solution is used as thedelivery vehicle solution, combination with an equal volume of a 1 mg/mlpolynucleic acid solution will yield a ratio of lipid-conjugatedpolyamide to polynucleic acid of 5 mg lipid-conjugated polyamide to 5 mgpolynucleic acid.

The first liquid carrier may be the same or different from the secondliquid carrier. Suitable first and second liquid carriers include theliquid carriers described herein. The term “delivery vehicle” usedherein refers to an ordered structure that is capable of complexing withor enveloping a polynucleotide. Suitable delivery vehicles includeliposomes, micelles, vesicles, and the like. As used herein, the term“delivery vehicle-forming compound” refers to a compound that is capableof forming a delivery vehicle. Exemplary delivery vehicle-formingcompounds include amphipathic lipids, non-lipid polycationic compounds,lipid-conjugated polyamide compounds, and the like.

After the dilute polynucleotide solution and delivery vehiclepreparation are combined, the volume of the resulting mixture isreduced. Suitable methods for reducing the volume of the resultingmixture include, for example, centrifugal filtration, vacuum filtration,as well as other methods for volume reduction that are well known tothose having ordinary skill in the art. Typically, the volume of theresulting mixture is reduced such that the concentration ofpolynucleotide in the preparation is greater than about 150 μg/ml. Thefinal concentration of the concentrated preparation can be lowered afterthe volume reduction step by adding sufficient liquid carrier to thepreparation to achieve the desired concentration.

As used herein, the term “precipitant-free” refers to a preparation orsolution that is free of solid material, i.e., precipitant material, asvisually detected by the naked eye.

It has been discovered that transfection of cells using stable deliveryvehicle/polynucleotide complex preparations is typically more efficientthan with complexes formed by the conventional method of mixing equalvolumes of dilute solutions of polynucleotide and delivery vehicletogether, immediately prior to transfection, as illustrated in FIG. 14.

The invention will now be described in greater detail with reference tothe following non-limiting examples.

EXAMPLE 1 Preparation of Lipid-Conjugated Polyamide Compounds A.Synthesis of Lipid-Conjugated Polyamide Compounds

(1) Synthesis of Oligomer Reactant

A fritted reaction vessel was charged with 100 mg of Fmoc-Rink amideresin with a substitution level of about 0.50 mmol/g resin. Twomilliliters of dimethylformamide CDMF) was added to the resin. Themixture was agitated for 1-2 minutes to swell the resin, then the DMFwas drained. The Fmoc groups were removed by adding 2.0 ml of 20%piperidine in DMF to the resin, then agitating for 1 minute. Thesolution was then drained from the resin. Another 2 ml of 20% piperidinein DMF was added to the resin, followed by agitation for 15 minutes,after which, the DMF was then drained from the resin.

The resin was washed by adding 2 ml of DMF to the resin, followed byagitation to form a uniform slurry. The resin slurry was agitated bybubbling argon up through the bottom of the fritted vessel. The DMF wasremoved from the resin by vacuum filtration through the fritted bottomof the reaction vessel until the resin appeared dry (typically about 5seconds). The washing step was repeated 6 times with DMF.

The deblocked amine was then acylated by adding 850 μl of 1.2 Mbromoactic acid in DMF to the resin, followed by 200 il ofN,N′-diisopropylcarbodiimide (DIC). This mixture was agitated for 45minutes at 35° C., then the solution was drained from the resin. Theresin was washed with 6×2 ml aliquots of DMF. Amine displacement waseffected by treating the resin with 850 μl of a 1 M solution of an aminein dimethylsulfoxide (DMSO). This mixture was agitated at 35° C. for 20minutes, then the amine solution was drained from the resin. After theamine displacement step, the resin was washed with 6×2 ml aliquots ofDMF. This completed one cycle of acylation and displacement.

The second cycle was initiated by acylation using bromoacetic acid andDIC, followed by displacement with a second amine as described above.This acylation/displacement cycle was repeated until the desiredoligomer was reached.

The N-terminus of the resulting oligomer was acylated at 35° C. for 45minutes with 850 μl of bromoacetic acid in DMF (1.2 M) and 200 μl DIC.

(2) Displacement of Bromide from Bromoacetylated Oligomer Reactant withDimyristoyl Phosphatidylethanolamine

A quantity of 254 mg of dimyristoyl phosphatidylethanolamine (DMPE)(Genzyme, Cambridge, Mass.) was suspended in 2 ml of 15% methanol inchlorobenzene, then treated with 30 μl of 12.8 N aqueous KOH. Theresulting solution of DMPE was added to the bromoacetylated oligomer onresin from (1), above, and the reaction was agitated by bubbling argonfor 1 second every 30 seconds over a period of 14 hours at 35° C. Next,the resin was thoroughly washed with 15% methanol in chlorobenzene toremove unreacted DMPE.

The resulting lipid-conjugated polyamide compound was cleaved from theresin and deprotected using 95% TFA in water, then lyophilized to yielda crude product.

This method was repeated using dipalmitoyl phosphatidylethanolamine(DPPE) and dioleoyl phosphatidylethanolarnine (DOPE). Lipid-conjugatedpolyamide compounds prepared in accordance with this method are show inTable 1 and Table 2 below.

TABLE 1 Lipid-Conjugated N-Substituted Polyglycine Compounds^(†)Compound No. n m R₁ R₄ 1 1 2 2-aminoethyl tridecyl 2 1 4 2-aminoethyltridecyl 3 1 10 2-aminoethyl tridecyl 4 1 2 2-aminoethyl pentadecyl 5 14 2-aminoethyl pentadecyl 6 1 10 2-aminoethyl tridecyl 7 1 23-aminopropyl tridecyl 8 1 4 3-aminopropyl tridecyl 9 1 10 3-aminopropyltridecyl 10 1 2 3-aminopropyl pentadecyl 11 1 4 3-aminopropyl pentadecyl12 1 10 3-aminopropyl pentadecyl ^(†)Compounds of formula (I) where W isCH₂, R_(c) is NH₂, and R_(a) is defined by formula (III), where p is 2.

TABLE 2 Examples of Lipid-Conjugated N-substituted Polyglycine CompoundsHaving Repeating Trimer Units^(†) Compound No. m R¹ ₁ R² ₁ and R³ ₁ R₄13 3 2-aminoethyl 2-phenylethyl tridecyl 14 3 2-aminoethyl(S)-1-methylbenzyl tridecyl 15 2 2-aminoethyl 2-(4′-methoxyphenyl)ethyltridecyl 16 3 2-aminoethyl 2-(4′-methoxyphenyl)ethyl tridecyl 17 42-aminoethyl 2-(4′-methoxyphenyl)ethyl tridecyl 18 8 2-aminoethyl2-(4′-methoxyphenyl)ethyl tridecyl 19 12 2-aminoethyl2-(4′-methoxyphenyl)ethyl tridecyl 20 3 2-aminoethyl2-(4′-methoxyphenyl)ethyl cis-8- heptadecyl 21 3 2-aminoethyl pentyltridecyl 22 3 2-aminoethyl pentyl cis-8- heptadecyl 23 3 2-aminoethyl3-methylbutyl tridecyl 24 3 2-aminoethyl 3-methylbutyl cis-8- heptadecyl^(†)Compounds of formula (IV) where W is CH₂, R_(c) is NH₂, and R_(a) isdefined by formula (III), where p is 2.

B. Characterization of Lipid-Conjugated Polyamide Compounds

The lyophilized crude product from part A was dissolved in 5 ml of 50%(v/v) acetonitrile in water, and resulting solution was applied to aDelta-Pak™ C4 column (15 μm 300 Å) equilibrated with 80% (v/v) solvent B(0.1% (v/v) TFA in acetonitrile) in solvent A (0.1% (v/v) TFA in water)on a Water Prep LC3000 system equipped with a UV detector (Waters Corp.,Milford, Mass.). Peaks were eluted with a linear gradient of 80% (v/v)solvent B in solvent A to 100% solvent B over 20 minutes, followed by100% solvent B for 15 minutes at a flow rate of 50 ml/min. Peaks weremonitored at 220 nm. the fractions containing the desiredlipid-conjugated polyamide compounds were combined and concentrated invacuo.

Products were characterized by analytical reverse phase HPLC using aVydac C4 column (5 μm 300 Å, 1.0×150 mm) on a MAGIC 2002 liquidchromatography system (Michrom BioResource, Auburn, Calif.) andelectrospray ionization mass spectrometry (Micromass, FISONSInstruments, Bevely, Mass.).

Chromatography of the reaction products from part A(2) of this examplegenerated large sharp peaks, which correspond to the lipid-conjugatedpolyamide compounds, and much smaller peaks, which correspond tounreacted oligomers. Mass spectroscopy confirmed the theoreticalmolecular weights of the synthesized lipid-conjugated polyamidecompounds from part A(2) in this example. Thus, these results confirmthe predicted molecular weights of the lipid-conjugated polyamidecompounds.

EXAMPLE 2 Preparation of Livid-Coniugated Polyamide Compounds Complexedwith Plasmid DNA

Lipid-conjugated polyamides (from Example 1) complexed with plasmid DNAwere prepared. The plasmid used in these experiments was pCMVkmLUC.Plasmid pCMVkmLUC was constructed by inserting the luc+ gene frompSP-luc+ (Promega Corp. Madison, Wiss.) into the expression vectorpCMVkm2. The sequence of vector CMVkm2 is depicted in SEQ ID NO: 1. Aplasmid map of vector CMVkm2 is shown in FIG. 2.

Briefly, pSP-1uc+ was digested with the restriction enzymes Nhel-EcoRV(Boehringer Mannheim, Indianapolis, Ind.) and a fragment of 1691 bp wasisolated by standard methods. This fragment was inserted into pCMVkm2,which had been digested with XbaI, EcoRV using the Rapid Ligation Kit(Boehringer Mannheim, Indianapolis, Ind.). The luc+ gene was cloned intopCMVkm2 such that expression is driven by the CMV immediate earlyenhancer promoter and terminated by the bovine growth hormonepolyadenylation signal.

Lipid-conjugated polyamide compounds synthesized in Example 1 weredissolved in sterile water at a concentration of 5 mM and sonicated for1 minute to get a clear solution. A 5 mM solution of pCMVkmLUC insterile water was prepared. Equal volumes of the lipid-conjugatedpolyamide compound solution and plasmid solution were mixed together andallowed to sit for 15 minutes at room temperature before transfection.For transfection studies, OptiMEM (GibcoBRL, Gaithersburg, Md.) was usedinstead of sterile water.

Complexes were also prepared by mixing lipid-conjugated polyamidecompounds with DOPE or cholesterol in an equal molar ratio, thensonicated to form liposomes. Plasmid DNA was then added to thesepreformed liposomes to form complexes.

Complexes of Lipofectin® (GibcoBRL, Gaithersburg, Md.) and DMRIE-C™(GibcoBRL, Gaithersburg, Md.) and plasmid DNA were also prepared ascontrols in the following examples, in accordance with manufacturer'sdirections.

EXAMPLE 3 Characterization of Lipid-Conjugated Polyamide CompoundsComplexed with Plasmid DNA

Rehydration of the lyophilized Compound 16 (see Table 2) in sterilewater produced a clear solution which did not scatter light. Undernegative-stain electron microscopy, the lipid-conjugated polyamidecompound in this solution appeared as aggregates of most cylindricalmicelles, with some spherical micelles with diameters of between about10 to about 15 nm. While mixing a solution of Compound 16 with thepCMVkmLUC solution from Example 3, dynamic light scattering measurements(N4 Plus, Coulter Instruments, Miami, Fla.) indicated that particlesizes reached a minimum of about 120 nm when the +/− charge ratio wasbetween about 2 and about 4. The particles sizes of these complexesincreased slightly as the charge ratio changed. Negative-stain electronmicroscopy of a 2:1 +/− charge ratio complex indicated the formation ofhomogeneous, spherical particles with diameters of around 150 nm.

Dynamic light scattering measurements were similarly taken while mixingCompound 23 with pCMVkmLUC. The particle sizes of the resultinglipid-conjugated polyamide/DNA complex reached a minimum of 120 nm whenthe +/− charge ratio was between about 2 and about 4. When the chargeratio increased or decreased, the particle sizes of these complexesincreased slightly.

Zeta potential measurements (Delsa 400, Coulter Instruments) indicatedthe zeta potential of the Compound 16/DNA complex increased steadily asthe ratio of lipid-conjugated polyamide to DNA increased, and chargeneutralization was realized at a charge ratio between about 0.5 and 1.

Complex formation was also characterized by agarose gel mobility shiftassay. Complexes of Compound 16 with 1 μg pCMVkmLUC at a +/− chargeratio of 1 or above, were loaded onto a 1% agarose gel (70V, 1 hour) toexamine the retardation of the complexed plasmid DNA, as compared tonaked plasmid DNA. Gel mobility shift confirmed that the plasmid DNA wasretained in the complex.

EXAMPLE 4 Characterization of DNA Stability in Complexes withLipid-Conjugated Polyamide Compounds

To determine whether lipid-conjugated polyamide compounds of the presentinvention inhibit degradation of complexed DNA by DNase I (BoehringerMannheim, Indianapolis, Ind.), lipid-conjugated polyamideIDNA complexeswere treated wih DNase I and the results were analyzed by agarose gelelectrophoresis. pCMVkmLUC (10 μg) and lipid-conjugated/pCMVkmLUCcomplexes containing 10 μg of pCMVkmLUC were incubated at 37° C. with 10units of DNase I in 50 μl of 10 mM MgCl₂ for 15 minutes. An aliquot (1μg DNA) of complex/DNase mixture was loaded (the loading buffercontained 1% SDS) onto a 1% agarose gel (70V, 1 hour) to examine theintegrity of the plasmid DNA.

The results indicated that lipid-conjugated polyamide compounds havingeither aromatic or aliphatic R₁ groups were effective at providingresistance to DNase degradation, however, aromatic R₁ groups appeared toprovide somewhat greater resistance to degradation. These resultssuggest that lipid-conjugated polyamide compounds having aromatic R₁groups complex more strongly with DNA.

Furthermore, lipid-conjugated polyamide compounds of formula (IV),having the R₁ ¹:R₁ ²:R₁ ³ motif ofaminoethyl:2-(4′-methoxyphenyl)ethyl:2-(4′-methoxyphenyl)ethyl, appearedto protect the plasmid DNA to a greater extent, than other motifs, asevidenced by the greater amount of supercoiled plasmid DNA retained.This result appeared to be independent of the length of thelipid-conjugated polyamide compound. Plasmid DNA stability was alsoevaluated as a function of complex +charge ratio.Lipitoid/polynucleotide complexes having different charge ratios wereprepared by mixing different amounts of Compound 16 with a fixed amountof plasmid DNA. No significant degradation was observed with any of thecharge ratios evaluated, i.e., +/− 10:1, 8:1, 4:1 and 2:1. However,supercoil conformation was maintained to a greater extent at highercharge ratios as compared to lower charge.

EXAMPLE 6 Transfection Method and Assay

Three cell lines were used in the transfection studies, HT1080 (AmericanType Culture Collection, Rockville, Md., Accession No. CCL 121), NIH3T3(from culture collection stock of Chiron Corp., Emeryville, Calif.), andCos6M (from laboratory of E. Glazer, Chiron Corp. Emeryville, Calif.).Prior to transfection, the cells (2 ml of a suspension of 1×10⁵ cells/mlDME-FCS) were plated into each well of a 6-well plate (Corning,Cambridge, Mass.) and moved gently to evenly disperse the cells. Thecells were transfected 24 hours later.

For transfection, both transient and stable complexes containing plasmid(GibcoBRL, Gaithersburg, Md.). A transfection medium of complexed DNAwas added to each well at 1 μg pCMVkmLUC/well, and at a concentration of1 μg/100 μl. All tested conditions were performed in duplicate wells.Cells were cultured with transfection medium for 3 hours at 37° C. Thetransfection medium was removed by pipet without disturbing the celllayer and replaced with 2 ml of either DME-FCS (for serum-positiveconditions) or OptiMEM (for serun-free conditions). The cells werereincubated for 48 hours, then the medium discarded. The cells were thenrinsed twice with DPBS (JRH Biosciences, Lenexa, Kans.)

Reporter lysis buffer (300 μI/well) (Promega Corp., Madison, Wiss.) wasadded to the wells and the cells were allowed to lyse for 15 to 20minutes on a rocker. The cell lysate from each well was transferred toan eppendorf tube using a cell scraper (Fisher Scientific, Pittsburgh,Pa.), followed by a freeze (ethanol-dry ice)-thaw cycle andmicrofugation at maximum speed for 2 minutes.

Firefly luciferase activity for the lysates was assayed using theLuciferase Assay Kit (Promega Corp., Madison, Wiss.) and an ML2250automated luminometer (Dynatech, Chantilly, Va.) in accordance withmanufacturer's directions.

EXAMPLE 7 Evaluation of Transfection Efficiency as a Function ofLipid-Conjugated Polyamide/DNA Complex Charge Density

Lipid-conjugated polyamide/DNA complexes were prepared from Compound 16and pCMVkmLUC in OptiMEM as described in Example 2, which had +/− chargedensities of 0.5:1, 1:1, 2:1, 4:1, and 8:1. HT 1080 cells weretransfected and assayed in accordance with the method described inExample 6. The relationship between transfection efficiency, i.e.,luciferase activity, and complex charge density is shown in FIG. 2. Theresults indicate that transfection of HT1080 cells using Compound 16 wasmost efficient when the +/− charge density of the complex was about 2:1.The results also indicate that serum did not appear to have asignificant influence on transfection efficiency.

EXAMPLE 8 Evaluation of the Effect of Olinomer Length on theTransfection Efficiency of Linid-Coniugated Polyamide Compounds

Lipid-conjugated polyamide/pCMVkmLUC complexes were prepared fromCompounds 15-19, having a +/− charge ratio of 2:1, in OptiMEM accordingto Example 2. Compounds 15-19 all have the same general structure, i.e.formula (IV), identical side chains and lipid groups, however, theydiffer with respect to oligomer length, i.e., the integer m is differentfor each of these compounds. The integer m is 2, 3, 4, 8, and 12, forCompounds 15, 16, 17, 18, and 19, respectively. HT1080 cells weretransfected with complexes prepared from each of these compounds, thenassayed as described in Example 6.

The results, shown in FIG. 3, indicate that for this particular seriesof compounds, transfection efficiency is highest for Compound 16 (m=3).

EXAMPLE 9 Effect of Lipid Moiety Type on Transfection Efficiency

Conjugated-lipid polyamide/pCMVk UC complexes were prepared fromCompounds 16 and 23, both DMPE-conjugated compounds, and Compounds 20and 24, both DOPE-conjugated compounds, having a +/− charge densityratio of 2:1, as described in Example 2. HT1080 cells were transfectedusing these complexes and transfection efficiency was assayed, both inaccordance with the methods described in Example 6

The results, shown in FIG. 4, indicated higher transfection efficienciesfor the DMPE-conjugated compounds, as compared to the DOPE-conjugatedcompounds.

EXAMPLE 10 Transfection of Different Cell Lines Using Lipid-ConjugatedPolyamide Compounds

Lipid-conjugated polyamide/pCMVkmLUC plasmid complexes were preparedfrom Compounds 16 and 23 in OptiMEM, having a +/− charge density ratioof 2:1, according to Example 2. In addition, Lipofectine/pCMVkmLUC andDMRIE-C™ /pCMVkmLUC complexes were prepared according to manufacturer'sdirections in OptiMEM. HT1080, Cos6M, and NIH3T3 cells were transfectedwith the complexes, and subsequently assayed for luciferase activityaccording to Example 6.

The results are shown in Table 3. These results demonstrate the highertransfection efficiencies of lipid-conjugated polyamide compounds, ascompared to commercially available transfection preparations.

TABLE 3 Transfection Efficiency^(†) of Lipid-Conjugated PolyamideCompounds Transfection Vehicle Compound Cell Line Lipofectin ® DMRIE-C ™16 Compound 23 HT1080 1/1^(a) 5.2/3^(a) 10/7^(a) 17.6/12.8^(a) COS6M1/1^(a) 8/27^(a) /26^(a) 3/29^(a) NIH3T3 1/1^(b) 100/33^(b) 0.76/4.9^(b)^(†)Normalized Luciferase Activity (optiMEM, serum-free)/NormalizeLuciferase Activity (serum) ^(a)Both serum and serum-free activities arenormalized to the corresponding luciferase activities fromLipofectin ®-mediated transfection. ^(b)Both serum and serum-freeactivites are normalized to the corresponding luciferase activities fromDMRIE-C ™-mediated transfection.

EXAMPLE 11 Transfection of HT1080 Cells Using Various Lipid-ConiugatedPolyamide Compounds

Lipid-conjugated polyamide/pCMVkmLUC plasmid complexes were preparedfrom some of the lipid-conjugated polyamide compounds from Example 1, inOptiMEM as described in Example 2. The complexes had a +/− chargedensity ratio of 2:1 In addition, Lipofectin®/pCMVkmnLUC andDMRIE-C™/pCMVkmLUC complexes were prepared according to manufacturer'sdirections in OptiMEM. HT1080 cells were transfected with the complexes,and subsequently assayed for luciferase activity according to Example 6.

The results are shown in below in Table 4.

TABLE 4 Transfection Efficiency^(†a) of Lipid-Conjugated PolyamideCompounds Transfection Vehicle Transfection Efficiency Lipofectin ® 1/1DMRIE-C ™ 5.2/3   Compound 2   2/0.2 Compound 3 1.6/1.3 Compound 80.1/0.1 Compound 9 0.1/0.1 Compound 13 4.3/3.2 Compound 14 5.7/4  Compound 15 4.1/2.4 Compound 16 10/7  Compound 17 1.7/1.1 Compound 204/3 Compound 21   6/9.3 Compound 22 3.5/6.2 Compound 23 17/12 Compound24   2/7.2 ^(†)Normalized Luciferase Activity (optiMEM,serum-free)/Normalize Luciferase Activity (serum) ^(a)All activitieswere normalized to the corresponding serum and serum-free luciferaseactivities from Lipofectin ®-mediated transfection.

Lipid-conjugated polyamide compounds having repeating n-mer units withboth cationic and neutral sidechains (R₁) were generally more effectiveat mediating transfection as compared to lipid-conjugated polyamidecompounds having only cationic sidechains.

EXAMPLE 12 In vivo Transfection Using a Lipid-Conjugated PolyamideCompound/ICMVkmLUC Complex

A preparation of lipid-conjugated polyamide/pCMVkmLUC complex wasprepared by mixing an 200 μl of a solution of 60 μg of pCMVkmLUC in 200μl of D5W (5% dextrose) with 200 μl of 2.9 mg of Compound 16 in 200 μlof D5W (5% dextrose), such that the complex +/− charge ratio was 8:1.The final volume of the lipid-conjugated polyamide/DNA complexpreparation was 400 μl. A 400 μl dosage of the preparation was injectedinto the tail vein of a Balb/C mouse.

The mouse was sacrificed 24 hours post-injection and the lungs, liver,heart, kidney, and spleen were harvested. The harvested organs wereplaced in 2.0 ml screwcap tubes in which one third of the volume of thetubes was filled with glass beads (BioSpec Products, Inc., Bartlesville,Okla.) Please provide source location. The tubes were frozen in liquidnitrogen, then stored at −70° C.

To extract luciferase from the harvested organs, a 300 μl aliquot of1×Reporter Lysis Buffer (Promega Corp., Madison, Wiss.) was added toeach tube. The contents of the tubes were then homogenized for 1 minuteat 4° C. After adding a 200 μl aliquot of 1×RLB to each tube, the tubecontents were vortexed for 30 minutes in the cold room. The tubes andtheir contents were then frozen in an ethanol/dry ice bath, then thawedin a water bath at 20° C., for three cycles. The tubes were thencentrifuged at 12,500 rpm for 5 minutes in a cold room. Aftercentrifugation, the supernatant was collected by pipet.

The supernatant was assayed for luciferase activity using the PromegaLuciferase assay system and the Dynatech ML2250 automated luminometer(Dynatech, Chantilly, Va.) in accordance with the manufacturer'sdirections.

The results, shown in FIG. 5, indicate that luciferase is expressed inmouse lung, liver, and, to a lesser extent, spleen tissue. These resultsdemonstrate the efficacy of lipid-conjugated polyamide compounds atmediating in vivo transfection.

EXAMPLE 13 Dilution-Concentration Method for Formulating StablePreparations of Delivery Vehicle/Polynucleotide Complexes

I. Charge Calculations

The concentration of negative charges on DNA was calculated as 3.03 nmolof phosphate per 1 μg of DNA based on an average molecular weight of 330daltons for each nucleotide. The formula weight of each lipid-conjugatedpolyamide compound was calculated as semi-trifluoroacetate salt (50% ofamino groups form salt with TFA), and the concentration of thelipid-conjugated polyamide compound was determined on the basis of thebasis of the lyophilized product from Example 1.

II. Complex Formation

All steps were conducted at ambient temperature. Diagnosis gradepurified water (DGPW) was used to prepare all stock solutions.Lipid-conjugated polyamide/pCMVkmLUC complexes were prepared having +/−charge ratios of 0.5: 1, 1:1, 2:1, 4: 1, and 8:1. A dilute solution of50 μg/ml polynucleotide in was prepared, corresponding to 151 μM ofnegative charge. A 5mM solutions of lipid-conjugated polyamide Compound16 was prepared.

A volume of the DNA solution was quickly added to an equal volume ofeach lipid-conjugated polyamide solution with gentle agitation. It wasobserved that slow addition of the two solutions tended to result in theformation of larger complexes and occasional precipitates. Betterresults were achieved when the DNA solution was added to thelipid-conjugated polyamide solution rather than vice-versa.

The formulations were concentrated using commercially availableultrafiltration membrane concentrator devices with appropriate nominalmolecular weight cutoff (e.g., 100 kd). Two milliliters of each dilutelipid-conjugated polyamide/pCMVkmLUC complex preparation (in 30% (v/v)ethanol) were placed in a Centricon® −100 (Amicon Inc., Beverly, Mass.)and centrifuged at 1000×g for 30 minutes or until the volume of theretentate contained the complex was approximately 50 μl. The filtratewas removed from the bottom receiver. The retentate was diluted with 2ml of 5% glucose, and concentrated to 50 μl again by repeating the aboveprocedure. This operation was repeated again to make a concentrated,stable preparation containing 1 mg/ml of pCMVkmLUC in 5% glucose. Themethod can be conducted cold (e.g., at 4° C.) or at ambienttemperatures. Generally, the final concentration of DNA in the retentatecan be as high as 1 mg/ml without any visible precipitation.

Zeta potential measurements were taken of each concentrated preparationat day 1, day 2, and day 8 post-formulation. The results, shown in FIGS.6 and 7, indicate that the zeta potential of the complexes in theconcentrated preparation remained substantially stable over a period of8 days.

Dynamic light scattering measurements (N4 Plus, Coulter Instruments,Miami, Fla.) were taken for each concentrated preparation oflipid-conjugated polyamide/pCMVkmLUC complex. The results, shown inFIGS. 8 and 9, indicate that the particle sizes of the complexes alsoremained substantially stable over a period of 8 days. HT 1080 cellswere transfected with each concentrated preparation oflipid-conjugated/pCMVkmLUC complex at 2- and 18-days post-formulation(Compound 16) and at 4- and 12-days post-formulation, according to themethod described in Example 6. A preparation of DMRIE-C™ /pCMVkmLUCcomplexes was prepared using conventional methods described in Example2, and TF1080 cells were transfected. Cell confluence was also measuredusing a microscope and estimating the percentage of live cells.

The results, shown in FIGS. 10-12 indicated that luciferase activity incells transfected with lipid-conjugated polyamide/pCMVkmLUC complexesprepared according to the “concentration” formulation method, was higherthan for DMRIE-Cm/pCMVkmnLUC complexes prepared according toconventional methods. The results indicate that cell confluence is highfor the 0.5:1, 1:1, and 2:1 +/− charge ratio complexes and the DMRIE-C™,and lower for the 4:1 and 8:1 +/1 charge ratio complexes. Doubling theamount of transfection preparation increased luciferase expression incomplexes having a 2:1 +/− charge ratio, but decreased expression incomplexes having a 4:1+/− charge ratio, as shown in FIG. 14. FIG. 14also shows that cell confluence also decreased when the amount of 4:1+/1 charge ratio complex was doubled.

The effect of using the conventional method for preparing deliveryvehicle/DNA complexes, as described in Example 2, was compared to use ofthe concentration method for preparing delivery vehicle/DNA complex.Lipid-conjugated polyamide compounds (16 and 23)/pCMVkmLUC complexeswere prepared according to the conventional method described in Example2. HT1080 cells were transfected within 30 minutes of formulation. Theresults are designated “Mixing” in FIG. 15. Similarly, lipid-conjugatedpolyamide compound (16 and 23)/pCMVkmLUC complexes were preparedaccording to the concentration method followed by transfection of HT1080cells 1 to 7 days post-formulation. The results are designated“Preformed” in FIGS. 14 and 15. Complexes of Lipofectin and DMRIE-C withpCMVkmLUC were also prepared using the conventional formulation methoddescribed in Example 2. The results, shown in FIG. 15, indicate thatluciferase activity was higher in cells transfected with complexesformed by the concentration method, than in cells transfected withcomplexes formed by the conventional method. Cell viability was measuredby staining with tryphan blue.

While the invention has been described in detail with reference tocertain preferred embodiments thereof, it will be understood thatmodifications and variations are within the spirit and scope of thatwhich is described and claimed.

1 4328 base pairs nucleic acid single linear DNA (genomic) 1 GCCGCGGAATTTCGACTCTA GGCCATTGCA TACGTTGTAT CTATATCATA ATATGTACAT 60 TTATATTGGCTCATGTCCAA TATGACCGCC ATGTTGACAT TGATTATTGA CTAGTTATTA 120 ATAGTAATCAATTACGGGGT CATTAGTTCA TAGCCCATAT ATGGAGTTCC GCGTTACATA 180 ACTTACGGTAAATGGCCCGC CTGGCTGACC GCCCAACGAC CCCCGCCCAT TGACGTCAAT 240 AATGACGTATGTTCCCATAG TAACGCCAAT AGGGACTTTC CATTGACGTC AATGGGTGGA 300 GTATTTACGGTAAACTGCCC ACTTGGCAGT ACATCAAGTG TATCATATGC CAAGTCCGCC 360 CCCTATTGACGTCAATGACG GTAAATGGCC CGCCTGGCAT TATGCCCAGT ACATGACCTT 420 ACGGGACTTTCCTACTTGGC AGTACATCTA CGTATTAGTC ATCGCTATTA CCATGGTGAT 480 GCGGTTTTGGCAGTACACCA ATGGGCGTGG ATAGCGGTTT GACTCACGGG GATTTCCAAG 540 TCTCCACCCCATTGACGTCA ATGGGAGTTT GTTTTGGCAC CAAAATCAAC GGGACTTTCC 600 AAAATGTCGTAATAACCCCG CCCCGTTGAC GCAAATGGGC GGTAGGCGTG TACGGTGGGA 660 GGTCTATATAAGCAGAGCTC GTTTAGTGAA CCGTCAGATC GCCTGGAGAC GCCATCCACG 720 CTGTTTTGACCTCCATAGAA GACACCGGGA CCGATCCAGC CTCCGCGGCC GGGAACGGTG 780 CATTGGAACGCGGATTCCCC GTGCCAAGAG TGACGTAAGT ACCGCCTATA GACTCTATAG 840 GCACACCCCTTTGGCTCTTA TGCATGCTAT ACTGTTTTTG GCTTGGGGCC TATACACCCC 900 CGCTCCTTATGCTATAGGTG ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT 960 ATTGACCACTCCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1020 GCCACAACTATCTCTATTGG CTATATGCCA ATACTCTGTC CTTCAGAGAC TGACACGGAC 1080 TCTGTATTTTTACAGGATGG GGTCCATTTA TTATTTACAA ATTCACATAT ACAACAACGC 1140 CGTCCCCCGTGCCCGCAGTT TTTATTAAAC ATAGCGTGGG ATCTCCGACA TCTCGGGTAC 1200 GTGTTCCGGACATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC 1260 CCATCCGTCCAGCGGCTCAT GGTCGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG 1320 ACTTAGGCACAGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG 1380 GTATGTGTCTGAAAATGAGC TCGGAGATTG GGCTCGCACC TGGACGCAGA TGGAAGACTT 1440 AAGGCAGCGGCAGAAGAAGA TGCAGGCAGC TGAGTTGTTG TATTCTGATA AGAGTCAGAG 1500 GTAACTCCCGTTGCGGTGCT GTTAACGGTG GAGGGCAGTG TAGTCTGAGC AGTACTCGTT 1560 GCTGCCGCGCGCGCCACCAG ACATAATAGC TGACAGACTA ACAGACTGTT CCTTTCCATG 1620 GGTCTTTTCTGCAGTCACCG TCGTCGACCT AAGAATTCAG ACTCGAGCAA GTCTAGAAAG 1680 CCATGGATATCGGATCCACT ACGCGTTAGA GCTCGCTGAT CAGCCTCGAC TGTGCCTTCT 1740 AGTTGCCAGCCATCTGTTGT TTGCCCCTCC CCCGTGCCTT CCTTGACCCT GGAAGGTGCC 1800 ACTCCCACTGTCCTTTCCTA ATAAAATGAG GAAATTGCAT CGCATTGTCT GAGTAGGTGT 1860 CATTCTATTCTGGGGGGTGG GGTGGGGCAG GACAGCAAGG GGGAGGATTG GGAAGACAAT 1920 AGCAGGGGGGTGGGCGAAGA ACTCCAGCAT GAGATCCCCG CGCTGGAGGA TCATCCAGCC 1980 GGCGTCCCGGAAAACGATTC CGAAGCCCAA CCTTTCATAG AAGGCGGCGG TGGAATCGAA 2040 ATCTCGTGATGGCAGGTTGG GCGTCGCTTG GTCGGTCATT TCGAACCCCA GAGTCCCGCT 2100 CAGAAGAACTCGTCAAGAAG GCGATAGAAG GCGATGCGCT GCGAATCGGG AGCGGCGATA 2160 CCGTAAAGCACGAGGAAGCG GTCAGCCCAT TCGCCGCCAA GCTCTTCAGC AATATCACGG 2220 GTAGCCAACGCTATGTCCTG ATAGCGGTCC GCCACACCCA GCCGGCCACA GTCGATGAAT 2280 CCAGAAAAGCGGCCATTTTC CACCATGATA TTCGGCAAGC AGGCATCGCC ATGGGTCACG 2340 ACGAGATCCTCGCCGTCGGG CATGCGCGCC TTGAGCCTGG CGAACAGTTC GGCTGGCGCG 2400 AGCCCCTGATGCTCTTCGTC CAGATCATCC TGATCGACAA GACCGGCTTC CATCCGAGTA 2460 CGTGCTCGCTCGATGCGATG TTTCGCTTGG TGGTCGAATG GGCAGGTAGC CGGATCAAGC 2520 GTATGCAGCCGCCGCATTGC ATCAGCCATG ATGGATACTT TCTCGGCAGG AGCAAGGTGA 2580 GATGACAGGAGATCCTGCCC CGGCACTTCG CCCAATAGCA GCCAGTCCCT TCCCGCTTCA 2640 GTGACAACGTCGAGCACAGC TGCGCAAGGA ACGCCCGTCG TGGCCAGCCA CGATAGCCGC 2700 GCTGCCTCGTCCTGCAGTTC ATTCAGGGCA CCGGACAGGT CGGTCTTGAC AAAAAGAACC 2760 GGGCGCCCCTGCGCTGACAG CCGGAACACG GCGGCATCAG AGCAGCCGAT TGTCTGTTGT 2820 GCCCAGTCATAGCCGAATAG CCTCTCCACC CAAGCGGCCG GAGAACCTGC GTGCAATCCA 2880 TCTTGTTCAATCATGCGAAA CGATCCTCAT CCTGTCTCTT GATCAGATCT TGATCCCCTG 2940 CGCCATCAGATCCTTGGCGG CAAGAAAGCC ATCCAGTTTA CTTTGCAGGG CTTCCCAACC 3000 TTACCAGAGGGCGCCCCAGC TGGCAATTCC GGTTCGCTTG CTGTCCATAA AACCGCCCAG 3060 TCTAGCTATCGCCATGTAAG CCCACTGCAA GCTACCTGCT TTCTCTTTGC GCTTGCGTTT 3120 TCCCTTGTCCAGATAGCCCA GTAGCTGACA TTCATCCGGG GTCAGCACCG TTTCTGCGGA 3180 CTGGCTTTCTACGTGTTCCG CTTCCTTTAG CAGCCCTTGC GCCCTGAGTG CTTGCGGCAG 3240 CGTGAAGCTGTCAATTCCGC GTTAAATTTT TGTTAAATCA GCTCATTTTT TAACCAATAG 3300 GCCGAAATCGGCAAAATCCC TTATAAATCA AAAGAATAGC CCGAGATAGG GTTGAGTGTT 3360 GTTCCAGTTTGGAACAAGAG TCCACTATTA AAGAACGTGG ACTCCAACGT CAAAGGGCGA 3420 AAAACCGTCTATCAGGGCGA TGGCGGATCA GCTTATGCGG TGTGAAATAC CGCACAGATG 3480 CGTAAGGAGAAAATACCGCA TCAGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG 3540 CTCGGTCGTTCGGCTGCGGC GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC 3600 CACAGAATCAGGGGATAACG CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG 3660 GAACCGTAAAAAGGCCGCGT TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA 3720 TCACAAAAATCGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA 3780 GGCGTTTCCCCCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG 3840 ATACCTGTCCGCCTTTCTCC CTTCGGGAAG CGTGGCGCTT TCTCATAGCT CACGCTGTAG 3900 GTATCTCAGTTCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT 3960 TCAGCCCGACCGCTGCGCCT TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA 4020 CGACTTATCGCCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG 4080 CGGTGCTACAGAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA GGACAGTATT 4140 TGGTATCTGCGCTCTGCTGA AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA GCTCTTGATC 4200 CGGCAAACAAACCACCGCTG GTAGCGGCGG TTTTTTGTTT GCAAGCAGCA GATTACGCGC 4260 AGAAAAAAAGGATCTCAAGA AGATCCTTTG ATCTTTTCTA CTGAACGGTG ATCCCCACCG 4320 GAATTGCG4328

What is claimed:
 1. A composition comprising a biologically active agentand a lipid-conjugated polyamide compound comprising a repeating trimerof monomeric subunits and having the formula:

 where m is an integer selected from 2 to about 48, Ra is selected fromthe group consisting of —OH, —H, —SH, —COOH, sulfonyl, a C1-C8 aliphaticgroup or a C3-C12 aryl, arylalkyl, arylalkenyl, or arylalkynyl group,any of which may include at least one heteroatom selected from the groupconsisting of nitrogen, sulfur, oxygen, and phosphorus; and a lipidmoiety, wherein said lipid moiety may be conjugated to a linker moiety:each R₁ is independently selected from the group consisting of hydrogen,a C1-C8 aliphatic group or a C3-C12 aryl, arylalkyl, arylalkenyl, orarylalkynyl group, any of which may include at least one heteroatomselected from the group consisting of nitrogen, sulfur, oxygen, andphosphorus; and a lipid moiety, wherein said lipid moiety may beconjugated to a linker moiety, wherein at least one group R₁ is nothydrogen; Rc is selected from the group consisting of —OH, —H, —SH,—NH₂, sulfonyl, hydrazine, a C 1-C8 aliphatic group or a C3-C12 aryl,arylalkyl, arylalkenyl, or arylalkynyl group, any of which may includeat least one heteroatom selected from the group consisting of nitrogen,sulfur, oxygen, and phosphorus; and a lipid moiety, wherein said lipidmoiety may be conjugated to a linker moiety; and each group W isselected from the group consisting of —CH₂CH₂—, —CH₂phenyl—, CH₂CH₂O—,—CH₂CH═CH—, and —CR₂R₃—, where R₂ and R₃ are independently selected fromthe group consisting of hydrogen, a C1-C8 aliphatic group or a C3-C12aryl, arylalkyl, arylalkenyl, or arylalkynyl group, any of which mayinclude at least one heteroatom selected from the group consisting ofnitrogen, sulfur, oxygen, and phosphorus; and a lipid moiety, whereinsaid lipid moiety may be conjugated to a linker moietv; wherein any saidaryl, arylalkyl, arylalkenyl, or arylalkynyl group having fewer than 5carbon atoms further includes at least one heteroatom; and wherein atleast one of said groups R_(a), R_(c), R₁ for a single monomericsubunit, and W for single monomeric subunit, comprises a lipid moiety.2. A method for inducing the uptake of a biologically active agent by acell, said method comprising contacting said cell with a compositioncomprising an effective amount of the biologically active agent and alipid-conjugated polyamide compound as recited in claim
 1. 3. The methodaccording to claim 2, wherein said biologically active agent is apolynucleic acid.
 4. The method of claim 2, wherein said uptake is invivo, and said contacting comprises administering an effective dose ofsaid composition to a subject.
 5. The method according to claim 4,wherein said biologically active agent is a polynucleic acid.
 6. Themethod of claim 4, said composition comprises a polynucleic acidcomplexed with a lipid-conjugated polyamide compound as recited in claim4, and said subject is a mammal, wherein said polynucleic acid iscapable of functionally expressing said gene in said mammal, and whereinsaid complex is effective at transfecting said gene into a cell in saidmammal.
 7. A method for substantially inhibiting nuclease-inducedpolynucleotide degradation, said method comprising contacting apolynucleotide with a dlegradation-inhibiting quantity of the lipidconjugated polyamide compound as recited in claim 1, and introducingsaid polynucleotide and said lipid-conjugated polyamide compound into anuclease-containing environment.
 8. The composition of claim 1, whereinsaid lipid is a C14 to C50 aliphatic, aryl, arylalkyl, arylalkenyl, orarylalkynyl moiety, which may include at least one heteroatom selectedfrom the group consisting of nitrogen, sulfur, oxygen, and phosphorus.9. The composition of claim 1, wherein said lipid is a phosphoglyceride,a glycosylglyceride, a sphingolipid, or a sterol.
 10. The composition ofclaim 1, wherein at least one group R₁ is a cationic sidechain selectedfrom the group consisting of aminoalkyl, (S)-α-methylethylenediamino,trimethylaminoethyl, guanidinoalkyl, aminobenzyl, pyridinium, cationicsidechains found on naturally occurring amino acids, and derivativesthereof.
 11. The composition of claim 1, wherein at least one group R,is a neutral sidechain selected from the group consisting of(S)-α-methylbenzyl, (R)-α-methylbenzyl, benzyl, phenethyl,naphthylmethyl, (S)-α-methylnaphthyl, (R)-α-methylnaphthyl,N-propylpyrrolidinone, cyclohexylmethyl, furfuryl,3,4,5-trimethoxybenzyl, alkoxyalkyl, isoamyl, p-methoxyphenethyl,neutral sidechains found on naturally occurring amino acids, andderivatives thereof.
 12. The composition of claim 1, wherein at leastone group R₁ is an anionic side chain selected from the group consistingof carboxy, carboxy methyl, carboxy ethyl, benzoic acid, phosphates,sulfates, and derivatives thereof.
 13. The composition of claim 1, whereeach group W is —CR₂R₃—.
 14. The composition of claim 13, where R₂ andR₃ are hydrogen.
 15. The composition of claim 14, wherein R_(a) isselected from the group consisting of —OH, —H, —SH, —COOH, sulfonyl, anda lipid moiety, wherein said lipid moiety may be conjugated to a linkermoiety.
 16. The composition of clain 14, wherein R_(c) is selected fromthe group consisting of —OH, —H, —SH, —NH₂, sulfonyl, hydrazine, and alipid moiety, wherein said lipid moiety may be conjugated to a linkermoiety.
 17. The composition of claim 14, wherein Rc is a lipid moiety,which may be conjugated to a linker moiety.
 18. The composition of claim17, wherein said lipid moiety is a sterol.
 19. The composition of claim14, wherein Ra is a lipid moiety, which may be conjugated to a linkermoiety.
 20. The composition of claim 19, wherein said lipid moiety is aphosphatidyl ethanolamine or a phosphatidyl propanolamine, having aphosphoglyceryl head group comprising two alkyl or alkenyl moietieshaving from 6 to about 25 carbon atoms.
 21. The composition of claim 19,wherein said lipid moiety is a sterol.
 22. The composition of claim 21,wherein said sterol is a cholesterol.
 23. The composition of claim 22,wherein R₁ ¹ is a cationic sidechain, and R₁ ² and R₁ ³ are neutralsidechains.